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Abstract  
Cervical cancer is the fourth most common cancer in women and the cytological 
screening represents the most diffuse method of prevention. Human papillomavirus (HPV) is 
an established essential etiological factor for this cancer. Persistence of HPV infection, 
particularly by those belonging to the high-risk types (HR-HPV), is associated with an 
increased risk for cervical cancer development. Low-risk HPV (LR-HPV) types are more 
often associated with benign warts. Most invasive carcinomas are caused by two HR-HPV 
types: HPV16 and 18. Recently, HPV tests are used as an adjunct test to decrease the false-
negative rate of cytological screening with Papanicolaou test (PAP Test), especially HR-HPV 
DNA detection tests are useful for primary screening of cervical cancer and for triage of 
patients with equivocal cytological findings. However, the roles and contributions of other 
uncommon and rare genotypes remain uncertain, especially in specific geographic areas or 
populations. Recently, microarray biochip technology has been introduced into the clinical 
laboratory for HPV detection. One such test is the ProDect® CHIP HPV TYPING KIT (bcs 
Biotech Srl, Italy), which has the ability to identify 19 HPV types (all HR-HPV and most 
common LR-HPV types) and detect the generic presence of E6/E7 HR-HPV sequences. The 
aim of this pilot study was design a new biochip (CHIP PLUS) for the cervical cancer 
screening able to detect a large number of HPV anogenital types (HR- and LR-HPV) using 
two regions of the viral genome (L1 and E6/E7 sequences) as targets. This report also 
presents the results of a preliminary validation study in preparation for an extended clinical 
validation of the medical diagnostic ProDect® CHIP HPV TYPING PLUS employing the 
above CHIP PLUS designed both for the simultaneous detection of 31 HPV types (both 
common and uncommon HPV types) and for the characterization of three E6/E7 consensus 
sequences belonging to the principal groups of HR-HPV. The preliminary results of the 
ProDect® CHIP HPV TYPING PLUS KIT validation had higher concordance and/or greater 
compatibility with those of the reference tests, underlining the importance of searching for 
uncommon HPV types, enabling good prevention of cervical cancer using HPV DNA as test 
screening. 
III 
Preface 
 
This thesis is subdivided in two chapters on the different research activities I have 
conducted and about the research programs in which they were entered. All activities 
described were carried out at the University of Cagliari laboratories and bcs Biotech Srl 
Research and Development laboratories, a company specialized in the development and 
production of in Vitro Diagnostic Devices (IVD) and biotech platforms, certified UNI EN 
ISO 9001: 2008 and UNI CEI EN ISO 13485: 2012, http://www.biocs.it.  
 
The first chapter (Chapter 1), which is also the main topic of discussion for this thesis, 
with regards to the development and validation of a biochips Nucleic Acid Test (NAT) to be 
applied to the screening of cervical cancer and to the diagnosis of infection by Human 
Papillomavirus (HPV). This research commenced using a bcs Biotech biochip kit that can 
detect 19 HPV genotypes in anogenital tropism, including 14 HPV genotypes considered at 
high-risk oncogenic and clinically validated as CE IVD. These kits have been used in an 
International cooperation program funded by the Region of Sardinia (L.R. 1996 ART.19) 
entitled Screening of the human papilloma virus (HPV), and prevention of cervical cancer in 
women of the city of Cotonou and Benin coordinated by the Cytomorphology Department of 
the University of Cagliari in which bcs Biotech Srl attended as a partner and the scientific 
coordinator was Prof. Paola Sirigu. At the end of my study this biochip was implemented with 
further 12 genotypes, for a total of 31 detectable HPV genotypes, including many medium 
risk oncogenic genotypes that were not sufficiently investigated by an epidemiological point 
of view for their transforming power. This new test also allows, on the basis of additional 
probes, to detect and discriminate the three main groups of Early sequences (E6/E7) HPV, 
that are related only to these and other common genotypes with high-medium oncogenic risk. 
In fact, the proteins encoded by these sequences in the HPV genotypes with high oncogenic 
risk factors would be necessary, although not sufficient, for the neoplastic transformation of 
the mucosa. The study was suitable for the publication of an article on the first chip F.Piras, 
M.Piga, A. De Montis, R.F.Zannou Ahissou et.al. Prevalence of human papillomavirus 
infection in women in Benin, West Africa. Virology Journal 2011, 8:514   
http://www.ncbi.nlm.nih.gov/pubmed/22074103 and obtained a European Patent, also 
including the design of the new chip,  Perseu S., De Montis A., Lauterio C., Manca I. European 
Patent EP 1818416B1 
http://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=2012122
IV 
6&DB=&locale=en_EP&CC=EP&NR=1818416B1&KC=B1&ND=1. The new prototype kit 
clinical validations on chip are ongoing. In this thesis are only show some preliminary 
verification data obtained on pre-production batches, before the start of the clinical trials. 
 
The second chapter (Chapter 2) concerns a study in which I have participated at the end 
of the program POR 3.13 "Creating a center of excellence for bio-informatic technologies 
applied to personalized medicine" managed by Sardegna Ricerche. In fact, thanks to two 
different projects funded between 2006 and 2009 under this program entitled respectively 
“Development of new bioinformatics methods for the detection of environmental and genetic 
causes of multifactorial diseases in Ogliastra” and “Detection of the genes responsible for 
autoimmune Hypothyroidism and for Hashimoto Disease in Ogliastra”, at the BCS 
BIOTECH R & D laboratories was created a bio-bank including DNA from control subjects, 
verified by anamnestic and instrumental evaluation, as unaffected by the 20 most common 
multifactorial diseases in Sardinia (including Diabetes I and II, Multiple Sclerosis, 
Hypothyroidism and Hashimoto's disease, Lupus, Rheumatoid Arthritis etc.) and conversely 
subjects affected by these diseases. The samples collected in the BCS BIOTECH Bank, 
include sick individuals as well as healthy ones, carefully selected with a series of 
fundamental criteria: not related (based on their family tree up to 4th – 5th generation), 
coming from the same Mendelian Unit Cross (UMI) or geographic area. Starting from this 
assumption I proceeded to analyze control samples from the bcs Biotech bio-bank selected in 
the Ogliastra geographical area (central-eastern region of Sardinia) by the Affymetrix 
Genome-Wide Human SNP Array 6.0 platform localized at the Laboratory of Genomic in the 
Technology Park of Sardinia (Pula, Cagliari). At the same time, other colleagues from the 
Department of Experimental Biology, University of Cagliari, coordinated by Prof. Vona, were 
analyzing DNA of subjects collected in South Sardinia. This type of platform is able to 
simultaneously determine the genotype of a subject for about 1,000,000 Single Nucletides 
Polimorphic site (SNPs) and about a million genetic polymorphisms linked to the variation of 
the number of sequences (Copy Number Variation, CNV) data analysis was performed by 
using a dedicated software: the Genotyping Console™ software 4.0. The study and the 
merging of data from the samples collected both in bcs Biotech and from the University of 
Cagliari has been the subject of the following publication Piras I., De Montis A., Calò CM., 
Marini M., Atzori M., Corrias L., Sazzini M., Boattini A., Vona G., Contu L. Genome wide 
scan with nearly 700.000 SNPs in two sardinian subpopulations suggest some regions as 
V 
candidate targets for positive selection. European Journal of Human Genetics (EJHG) 2012, 
03:1-7 
http://www.ncbi.nlm.nih.gov/pubmed/22535185. The article highlights a sub structure 
of the Sardinian population, particularly in the area of Ogliastra presenting greater genetic 
homogeneity compared to a higher genetic variability in the samples from the south of the 
island. Following this publication I have been involved in an international study regarding the 
validation of an algorithm structure of geographical population (GPS) that exploits the data 
using as a reference SNPs 40000-130000, and on this assumption is able to determine the 
location geographic or genetic origin of any individual. Several research groups around the 
world have offered their dataset to allow the validation of the new algorithm model. 
Following the data this new genetic GPS placed 83% of the individuals studied in their 
country of origin. When applied to the Sardinian samples studied by myself, the GPS placed a 
quarter of them in their villages, and a majority of others within 50 km of their originating 
villages. http://www.ncbi.nlm.nih.gov/pubmed/24781250, Elhaik E, Tatarinova T, Chebotarev 
D, Piras IS, Maria Calò C, De Montis A, Atzori M, Marini M, Tofanelli S, Francalacci P, 
Pagani L, Tyler-Smith C, Xue Y, Cucca F, Schurr TG, Gaieski JB, Melendez C, Vilar MG, 
Owings AC, Gómez R, Fujita R, Santos FR, Comas D, Balanovsky O, Balanovska E, Zalloua 
P, Soodyall H, Pitchappan R, Ganeshprasad A, Hammer M, Matisoo-Smith L, Wells RS; 
Genographic Consortium. Geographic population structure analysis of worldwide human 
populations infers their biogeographical origins. Nature Communications. 2014 Apr 
29;5:3513.  
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CHAPTER 1 - DEVELOPMENT AND VALIDATION OF A NUCLEIC ACID TEST 
(NAT) MULTI-TARGET OF BIOCHIPS TO SCREEN UTERINE CERVIX CANCER 
 
1. Introduction 
The discovery of some genotypes of the human papillomavirus (HPV), defined as high-
risk oncogenic (HR), at the base of the etiopathogenesis cervical carcinomas[1] laid the 
foundation for the approach prior to the illness today, to the development of two prophylactic 
vaccines[2-10]: Gardasil® (Merck & Co.) and Cervarix (GlaxoSmithKline). Randomized 
controlled trials have demonstrated the efficacy for at least eight years[11] using the first 
vaccine Gardasil, also known as quadrivalent vaccine, in preventing infection by HPV-16 and 
HPV-18, together responsible for over 70% of carcinomas, and types HPV-6 and HPV-11, 
etiologic agents of 90% of anogenital warts, while Cervarix, also called bivalent, was 
protective about the development of forms precancerous and cancer caused by HPV-16 and 
HPV-18. Unfortunately, these vaccines do not prove, however, any therapeutic efficacy. 
 
The enhancement of diagnostic techniques, especially on the molecular sector, led till 
now the discovery of about forty HPV with high tropism towards the anogenital mucosa, 
including at least a dozen types, with regards to HPV-16 and HPV-18, with an elevated 
oncogenic propensity. 
 
The importance of these molecular studies in primary screening of cervical cancer is 
now irreplaceable, often resulting comparable[12-16], when not superior, to the Papanicolaou 
cytology Test (PAP test), that entrust pathologist to the lesions detection in mucosal according 
to a scale based on the parameters defined. This test still suffers from the suitability of the 
sampling and the subjectivity of interpretation, despite having been recently introduced some 
automation. 
 
In particular, several controlled studies demonstrate the high predictive value of HPV 
negative DNA, compared to the PAP test, indicating that, if confirmed, would allow the 
lengthening of the organized screening (3 to 5 years)[17-21] with a relative rationalization of 
health spending without reduction against the surveillance capabilities of this type of tumor. 
2 
The negative predictive value (NPV) of the molecular test takes on great importance because 
if the cervical cancer recognized as the main cause of persistent infection (ie for several years) 
by HPV genotypes with high oncogenic power, the probability that a woman developments, 
relatively quickly (within 5 years), preneoplastic or neoplastic lesions is statistically unlikely 
if the woman is HPV negative, then is free of any infection. 
 
As an example below there is one of the many screening algorithms proposed[18] which 
provides as the primary test, the only molecular test, and proposes the PAP test, so the 
evaluation of cytological abnormalities, only to those women positive for HPV sequences 
(Fig.1). 
 
WOMEN AGED 25 - 64 YEARS
HPV TEST
Negative Positive
Normal or
Borderline 
Mild or Positive 
Cytology Negative
HPV Negative    Cytology Mild or Positive
HPV Positive 
Cytology  Negative 
CYTOLOGY
COLPOSCOPYHPV & CYTOLOGY
at 6 – 12 months
COLPOSCOPY
NORMAL 
5 YEAR RECALL
HPV & CYTOLOGY
at 6 – 12 months
NORMAL 
5 YEAR RECALL
HPV Negative 
Cytology Borderline
Fig. 1[18] - An example of the proposed algorithm to screen for cervical cancer suggests that HPV DNA testing 
women as the primary test and cytological analysis of women HPV-positive as triage test. (Edited by Cuzick et 
al, 2008). 
 
However, the high predictive value of a negative HPV DNA test implies that the test 
used to perform molecular diagnosis can be attributed reliably negative for HPV DNA. 
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Unfortunately, little is still known about the natural history of HPV in relation to the 
development of cancer and in many ways very complex, influenced by 1) the ability of the 
virus to persist in episomal form or integrate into the genome of the host cell, 2) from high 
number of viral genotypes with variable oncogenic power, 3) from their interaction in the case 
of co-infection and 4) interaction with various genetic and molecular aspects of the host who 
would control the course of the disease. This means that many negative molecular diagnosis 
for HPV infection are not really reliable, (false negatives), but affected, as well as unsuitable 
withdrawals, by low power of the diagnostic tests on the market, especially to those more 
insidious viral forms, due to integration, co-infection or not widespread, but still equipped 
with a tumorigenic influences, at the base of recurrence or lesions of uncertain cytology 
classification (ASCUS), which can already show frank precancerous lesions through focused 
colposcopic analysis. 
 
The present research project can be included in this context since its general objectives 
the design, development and validation of a multi-target Nucleic Acid Test (NAT) that 
complies with CE standards for In Vitro Diagnostics Devices (IVDs), has a high negative 
predictive value applied to cervical cancer screening with the most modern diagnostic 
algorithms. 
 
1.1 Epidemiology of cervical cancer 
One of the most important achievements in the medical oncology field in the last fifty 
years, is the huge progress made in reducing mortality and cervical cancer incidents, at least 
in the countries that have adopted health policies for primary screenings. Slow progressive 
malignant tumors, specifically invasive that develops in the cervix. This neoplasia until a few 
decades ago was the most common cancer and the most lethal in the female population and 
constituted the second tumor, in order of incidents of mortality in general population, second 
only to lung cancer. The data published by the World Health Organization (WHO)[22] in 
2014 showed that it is now the third tumor incidence and the fourth leading cause death from 
cancer among women.  
 
The basis of this success, on one hand, studies of Professor Georgios Papanicolaou on 
cervical-vaginal cytological diagnostic during the Second World War that led to the rapid 
spread from 1960 a budget and poorly invasive screening test, called in his honor PAP test, on 
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the other hand, the recognition of the fundamental role of the human papillomavirus (HPV) 
on the neoplastic transformation of cervical mucus cells, hypothesized for the first time by 
Professor Harald zur Hausen in 1975. 
 
These two factors, together with the progress of the methodologies and the refinement 
of diagnostic capabilities of uterine cervix pre-neoplastic lesions, as well as the use of large- 
mass scale screening, have led to a strong reduction in the incidences and mortality of this 
type of tumor. However, data of the report of the WHO[22] of 2014 referring to 2012, still 
recorded over half a million new cases, more than 270,000 deaths, with over 85% of cases 
and deaths in developing countries[22], where it is the leading cause of death in women aged 
between 15 and 44 years. 
 
1.2 HPV infection and the natural history of cervical cancer 
The neoplastic transformation requires a series of complex mechanisms interacting with 
each other, both endogenous and exogenous types, which act by determining on one hand, a 
persistent alteration of the viral DNA and cell metabolism and on the other hand, a kind of 
tolerance by the immune system of the host organism[23-24]. The model currently recognized 
as the most descriptive HPV infection in course in relation to the development of cervical 
carcinoma represented in Fig. 2. The woman acquires the infection through sexual contact 
from an infected partner, with greater prevalence at a younger age due to first sexual 
encounters or when frequent exposure combined with a lack of prior immunity. The incidence 
of HPV-infected women is thus particularly high during adolescence and early adulthood and 
decrease with the progress of age (incidence). The contracted infection, however, is confined 
and of course eliminated (clearance) within an average of 2 years. In 90% of cases[25-27] 
and about 60% of these infections determines a serum conversion, or specific antibody 
production of the infecting HPV genotype. 
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Normal 
cervix
Precancerous lesion
HPV  detection
Cancer
Mild cytologic
abnormalities
HPV infection Viral persistence 
HPV  seropositive
incidence
clearance
invasionprogression
regression
progression
Time‐ years
Latent infection
T= 0
Fig. 2[23] Natural history of cervical carcinogenesis, (Amended by Schiffman M, et al. 2011) 
 
Using a cytology PAP Test (Tab. 1), these women showed cervical dysplasia classified 
as low or moderate, such as the American classification established in 2001 in Bethesda, Low-
grade Squamous Intraepithelial Lesion (LSIL) or in the European classification, given by the 
Norwegian Ralph Richart in 1967, Cervical Intraepithelial Neoplasm (CIN I). Only infections 
that persist have a certain probability to progress to real precancerous lesions, identified as 
type HSIL or CIN 2-3. Between them only a small proportion, if left untreated, progresses to 
carcinoma after several years [28]. Among the risk factors that may further predispose more 
rapidly to cancer (varying between 3 to 20 years is observed) have been highlighted smoking 
[29-31], prolonged use of oral contraceptives[32] and the number of natural births[33]. It is 
estimated that approximately 60%, 40% and 33% of CIN1, CIN2 and CIN3 respectively 
regress spontaneously, a variable amount closed to 20-30% persists without development to 
more serious lesions, 10-20% progress from CIN1 to CIN3 and from CIN2 to CIN3; and a 
smaller portion (1% of CIN1, 5% of CIN2, and 12% of CIN3) can, if untreated, evolve to 
invasive carcinoma[34]. 
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Dysplasia  Bethesda Classificazion2001 
(used in cytology) 
Cervical intraepithelial 
neoplasia CIN and CGIN 
classification 
atypical squamous cells, 
not classifiable 
 
atypical squamous cells, 
not excluding high-grade 
lesions 
ASC-US  
 
 
ASC-H  
--- 
 
 
--- 
low grade, mild LSIL  CIN1 
CIN2  high grade, moderate to 
severe 
HSIL  
CIN3 
dysplasia endocervicale 
with atypical glandular 
cells 
  
Adenocarcinoma in situ 
AGC differentiated in: 
AGC-NOS not otherwise specified
AGC favor neoplastic 
 
AIS  
CGIN 
(low-grade) 
(high-grade) 
 
CGIN(high-grade) 
Tab. 1[34,35] Comparison of the principal terminology used to classify preinvasive intraepithelial lesions 
 
1.3 Phylogenetic and epidemiologic HPV classification  
The Papillomavirus derive their name from the Latin "papilla" or pustule and from 
Greek "oma" which means cancer, in fact discovered only in the twentieth century, the lesions 
caused by them in humans, as in animals, has been known since ancient times.  
 
Classified in the family of Papillomaviridae[36] divided into 16 genera, we find the 
human papillomavirus, phylogenetically distributed in five genus (Alpha, Beta, Gamma, Mu 
and Nu), which currently includes around hundred genotypes[37]. Genotypes are 
distinguished by gene sequence basis of the HPV L1 region, that are dissimilar from each 
other by more than 10% of the sequence basis, and are identified by a number (HPV16, 
HPV18, HPV6, etc). 
 
These are viruses that induce hyperproliferative lesions in multilayered epithelia 
squamous of the skin and mucous membranes resulting in the major cause of elementary 
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lesions, such as warts and complex pre-cancerous and cancerous lesions[38]. Those with 
cutaneous tropism are identified as epidermotropic and infect primarily the skin of the hands 
and feet. The target cells of HPV called mucosals are mainly located at labial mucosa, 
respiratory tract and anogenital area. The restricted replication to these two types of cells is 
influenced by the differentiation stage of these cells. 
 
There are about forty HPV genotypes that infect the mucosal and the anogenital area 
epithelia. Based on the frequency with which they were isolated in anogenital cancerous or 
precancerous lesions, they are divided into two groups[39-42]: 
 
 The HPV Low Risk (LR) with oncogenic low-risk, until now, were only isolated from 
benign lesions: HPV-6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108. 
 
 The HPV High Risk (HR) with high-medium oncogenic risk, are frequently associated 
to the appearance of malignant lesions: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66, 68, 73, 82. Sequences of HPV16 and HPV18 were found in approximately 50-
70% and 10-20% of cervical carcinomas respectively [42]. 
 
1.4 Virus structure 
Observed under a transmission electron microscope (TEM) the HPV is a small, naked 
virus, whose capsid is formed by 72 capsomers arranged as a symmetrical icosahedron, 
encompassing a circular double helix DNA genome, circa 8 kilobases[42] (Fig. 3). Each 
capsomer is composed of two proteins: 80% from the L1 protein of 57 kD and the remaining 
20% from the L2 protein of 43-53 kD. The genome is characterized by an 8-10 coding ORF 
sequence (Open Reading Frames) and by a non-coding region called LCR (Long Control 
Region) or URR (Upstream Regulatory Region) regulator of the viral replication and 
transcription, ranging in size between various genotypes of HPV[44]. The HPV ORF are 
divided into early regions (E "Early, E1-E8")[45] and late (L "Late" L1-L2)[46] encoding 
proteins. The L proteins are the viral capsid L1 and L2 proteins, only expressed in infected 
cells in the final stages of the viral replication cycle in a productive way, while the E proteins 
are regulators of the duplication process of the viral genome and work directly and indirectly 
on macromolecular synthesis of the host cell. Among them, the E6 and E7 proteins are critical 
in inducing the transformation, in the tumor sense of the cell[47-49]. These proteins interact 
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with several transcription factors, acting cellular proteins; on the one hand the inhibition of 
mutation repair in the genomic cell DNA reducing the levels of cellular p53 levels[50-51], 
therefore altering the control and shelter mechanisms that the cell enacts towards any damage 
to its genetic heritage. On the other hand, inducing cell multiplication through interaction with 
cellular co-factors (in particular the pRb)[52-54] normally down-regulated if not needed (Fig. 
4). The other interactions with various factors for regulation, expression and cell replication 
always lead to target inactivation/degradation or they involve directly or indirectly 
stimulation/activation. However, because of viruses are difficult to propagate in vitro, many 
targets or interactions are still unclear. 
 
 
Fig. 3[42] DNA HPV-16 (Modified from Muñoz et.al, 2006) 
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E6
E7
E6BP
MCM7
PDZ domain 
proteins
hADA3
E6AP
cMyc
P3000/CBP
E6TP1
hTert
NFX1-91
p53
P300/CBP
pCAF
HDACs
p105
p130
pRb
p21
p27
Cyclin 
A,E
p600
ATM
E2F6
Fig. 4[54] Some target cells for proteins E6 and E7 oncogene (Modified from Bodily et al., 2011) 
1.5 Virus replication cycle  
From a molecular point of view the replication of HPV arises from sequences placed in 
the viral genome region Upstream Regulatory Region (URR) (Fig. 5). Two polyadenylation 
signals define 3 groups of viral sequences, whose expression is regulated by cellular factors 
during the host cell differentiation specifically: the group of genes E1, E2, E4, E5, and E8 
involved in viral DNA replication and in transcriptional control; the group formed by the 
genes E6 and E7 that maintain and stimulate replication; and lastly the group of L sequences 
encoding the L1 and L2 capsid structural proteins. 
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E6
E7
E4 E5
E8
E1
E2
L2
L1
Enhancer
Ori
URR
Late poly-AEarly poly-A
E7
E1
E2
E4^5L2
L1
URR
E6
Fig. 5[54] Linearized genome of HPV (Modified from Bodily, 2011) 
The replicative cycle of the virus can be subdivided in a nonproductive stage called 
Early in which E sequences are transcribed and that lead to the functional synthesis factors, 
and then there is a productive stage called Late where the L regions transcription coding for 
the capsid structural factors. 
 
The non-productive stage is characterized by the stabilization of the viral genome as an 
episome at the basal layer level of the epithelium in which are localized cells in continuous 
division. In the cervix most infections are established at the level of the Transformation Zone 
(TZ) basal layer, the transition zone between the ectocervical stratified epithelium and of the 
endocervical columnar[54] (Fig. 6). Due to the effect of micro-trauma and to interaction with 
particular molecules[55], the HR or LR HPV reach the basal layer cells that are essentially of 
two types[56]: Transit Amplifying cells (TA), and proliferating cells capable of differentiating 
in a vertical direction moving to the mucosa suprabasal layers, and then the Stem cells (ST) 
who have a limited ability to proliferation, with the function of supply type TA cellular pool. 
Indeed, they represent the epithelium long-term reserve as only one of the two daughter cells 
derived from their division will become a TA cell while the other will remain ST; the 
mechanisms underlying this process are still unclear and very controversial. The virus would 
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infect electively the TA cells[57] replicating at the cell nucleus level its genome up to 50-200 
copies depending on the infecting genotype.  
 
The conservation of the episomal forms[58], essential for persistence phenomena 
establishment, it would be controlled by the sequences E6, E7, E1 and E2[59-62]. In fact, the 
E1 and E2 proteins cooperate with cellular factors to trigger viral genomes replication and E6 
and E7 proteins modulate the same factors so cell remains in active propagation as long as 
possible[63-64]. At this stage, the viral proteins are expressed at low levels and this 
contributes to evade the immune response by promoting the persistence. The newly formed 
viral genomes segregate in an equivalent manner between the two daughter cells at the time of 
mitotic division as cellular chromosomes[65] under E2 protein control. This protein also 
coordinates genomes number, which under physiological conditions must not exceed a certain 
threshold in order not to be lost during mitosis[66]. In this regard, E2 protein has functions of 
positive and negative control on E6, E7, E1 genes. When TA cell, under the effect of various 
factors, mainly of hormonal nature, is preparing to leave the basal layer to continue the 
differentiation, it has as a side effect a raising of transcription of ORFs. 
 
At the spinous layer level[67-69] is observed an impressive increase in E1, E2, E1 ^ E4 
and E5 transcripts[70-72] and viral genomic copies from 50-200 copies/cell reach up to about 
104-105 copies per cell[73]. Excess of E1 ^ E4 and E5 protein contributes, however, to the 
activation of L1 and L2 Late protein synthesis[74-76]. It follows that the capsid proteins, 
strongly immunogenic, are produced only in the more differentiated epithelial layer[77], that 
is the one that faces the organ lumen. 
 
The process of virus maturation from the deep layers to the release into the lumen 
requires long time, in the order of 4-6 months from the moment of infection contraction. 
 
Also the clearance of the virus, which occurs in the majority of infections, it would be a 
fairly slow process which involves cellular mediated immunity[78] although at present the 
mechanisms are known only in part[79]. HPV reduces the innate and acquired immune 
response through different strategies: for example, E6 and E7 cells expressing of HR HPV, 
repress transcription of many interferons target genes[80-83], while the HPV infected cells 
produce low levels of cytokines[84] such as IL-1, IL-6, TNF-α and TGF-β and high levels of 
anti-inflammatory IL-10 reducing the ability of immune cells to infiltrate the infected 
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tissue[85]. However in a certain proportion of HPV HR infections, viral genome tends to be 
integrated into the cellular DNA causing a reduced production of viral complete progeny. 
This integration is at the initialization of the transformation and cellular immortalization 
mechanisms, usually occurring at the E2 ORF level, resulting in loss of the repressive action 
on viral E2 factor on the E6 and E7 sequences transcription and consequently the production 
of relative proteins, fundamental in the mechanisms of carcinogenesis, and therefore 
considered viral oncoproteins[86-90] (Fig. 7). The interruption of the ORF at E2 and the 
subsequent integration of the HPV HR genome in the cell, leads to a consequent over-
expression of the E1, E6 and E7 proteins and amplification of their effects on the cell; 
stimulation of proliferation and the inhibition of p53-mediated control/repair mechanisms[89]. 
Studies conducted on HPV16 have shown that the viral DNA breaking points at the time of 
integration into the cellular genome can affect most of the virus genome[90]: only the L1-L2 
ORF have been with 59 breakpoints characterized and 39 breakpoints in E1-E2-E5 regions. It 
follows that the smallest region of the viral DNA, which, up to now a loss of sequence has not 
been observed, but that is fully detectable, both in episomal form and in integrated virus 
cellular genome, corresponds precisely to the regions URR, E6 and E7. 
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Fig. 7[87,90] Example of the HPV16 integration in the cellular genome with the interruption of the E2 sequence 
in HPV. Further potential breakpoints areas on the viral genome emphasized in the red region URR-E6 / E7 are 
apparently not subject to this phenomenon (modified from zur Hausen 2002 and Bo Xu, 2013). 
 
 
Considering what has been presented, HPV is a complex target from a diagnostic point 
of view. In fact, the infection may be observed in different stages: 
 
 productive with an elevated number of complete viral genomes 
 latent or persistent with controlled production of complete viral genomes  
 abortive with integrated and incomplete genomes  
 
Epidemiological data shows that majority of HPV infection heal due to host cell-
mediated immune response[91] and only 10% often persist and can potentially cause 
intraepithelial neoplasia to a various degree, which at a lower percentage may progress further 
to an invasive carcinoma[92-94]. This progression is due to many factors, among which 
significantly emerges the state of HPV HR virus integration[95-97] in the cellular genome. 
However it is not yet clear the influence of this integration in the progression of neoplastic 
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cell as it would seem a necessary element but not sufficient. In fact, several studies clarify the 
integrated forms pervasiveness in more advanced lesions[86,98-99], others report the 
concomitant presence of integrated and episomal forms already in CIN1[100-101], however 
with an increase of transcripts integrated forms higher in carcinomas than in CIN1[96] and of 
a certain intensity for high-risk oncogenic genotypes than others (Tab. 2)[97]. Furthermore, it 
is still controversial with regards to the diagnostic and prognostic role of high level E6/E7 
transcripts from integrated and episomal forms, given the increase has also been studied in 
women with integrated forms of HPV16, HPV18, HPV52 and HPV58, even in the absence of 
a pathological or normal cervix[102]. 
 
 
 Normal CIN1 CIN2 CIN3 Carcinoma 
HPV16 0 0 6% 19% 55% 
HPV18 0 0 0 0 92% 
HPV31 0 0 0 10% 14% 
HPV33 0 0 0 0 37% 
HPV45 0 0 3% 60% 83% 
Tab. 2[97] Prevalence transcribed E6 / E7 from HPV integrated forms (modified from Vinokurova 2008) 
 
 
It is obvious that a diagnostic system in line with the state of the art should be able to 
detect the virus even when the genomes are relatively few and especially not complete and the 
poor viral progeny or non-existent as in the case of abortive infections, since this is a 
condition that can meet these incurred infection with HPV HR clearance not naturally 
resolved by human host . 
 
1.6 Molecular diagnosis of HPV infection 
The release into the American/Asian market, rather than European of the In Vitro 
Diagnostic Medical Devices (IVDs) for the molecular diagnosis of HPV infections, is 
regulated by precise rules established through Control Authorities and sanctioned by a 
declaration of compliance with these standards, that is present in the documents 
accompanying the kit/product using two wording: Food and Drug Administration approval 
(FDA approval) and Conformité Européenne (CE). 
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The IVD applied to diagnostics of cervical cancer can be divided into 4 groups on the 
basis of the researched molecular marker, infection index, and molecular biology techniques 
used (Tab. 3)[23]. The first two groups include direct tests to highlight whether the viral 
nucleic acids, genomic DNA or virus transcripts (mRNA), while the other two groups 
comprise of indirect tests that detect the presence of HR virus for the effects it has on some 
metabolic cellular pathways related to the progression of CIN to carcinoma. 
 
The GROUP 1 tests have a target specific viral genome sequence that are captured 
through two general methods: direct hybridization with probes or by target gene amplification 
(PCR) using appropriate complementary sequences called primers; GROUP 2 tests highlight 
E6/E7 transcript genes using labeled probes after reverse transcription of messenger RNA 
(mRNA) into the complementary DNA (cDNA) and their cyclic amplification (TMA, 
NASBA); GROUP 3 reveal some cellular antigens by immunohistochemistry and GROUP 4 
some gene repeated sequences indicated by various studies as predictive markers of neoplastic 
transformation and progression by in situ hybridization (FISH). 
 
Each group of IVDs has their advantages but also the critical issues that limit its use at 
different diagnostic levels: in cervical cancer screening, in ASCUS triage, in the follow up of 
patients treated etc. 
 
GROUP 1 tests contemplate direct hybridization in liquid phase between a pool of full 
length complementary RNA probes to viral DNA. They are cheap, easy to use and 
theoretically detect the virus even in the case of incomplete genomes but actually do not 
typify the genotype, however they are not able to discriminate between single and multiple 
infections, nor estimate reliably the viral load that is calculated in a semiquantitative way by a 
chemiluminescence intensity gradient uncorrelated with the increase in the lesions severity.  
 
The other GROUP 1 tests instead amplify the viral DNA using primers more or less 
consensus depending on the PCR protocols, they are generally more expensive than direct 
hybridization, require dedicated areas for the dangerous environmental contamination and in 
general are directed on individual regions of the HPV genome, especially on L1 region. This 
has the advantage of being a highly conserved sequence of the HPV genome, on this base it is 
possible to assign the genotype. So normally they are test capable of highlighting multiple 
infections by different types. However, much like the other areas of the HPV genome, the 
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region L1 may be lost due to integration[90]. It follows, on average, a high specificity test 
which can detect from 13 HR HPV to 37 HPV (or almost all types in anogenital tropism) in 
front of a certain proportion of theoretical false negatives due to the integrated genomes 
potentially undetectable for types HR persistent. 
 
GROUP 2 instead belong to those kits that employ methodologies in Real Time, so in a 
semiquantitative way, amplify and detect using fluorophores marked probes and post reverse 
transcription in cDNA, mRNA from the E6/E7 viral oncogenes, whose levels are considered 
high prognostic index whether arising from integrated forms[97-102]. Although it is an 
expensive test that has the advantage of being in total automation even if in many cases do 
not define the infecting genotype but only positivity for HR HPV transcripts and are usually 
used as a second level test, namely in patients with a prior diagnosis and/or in follow-up post 
treatment. 
 
GROUP 3 includes tests can immunoquantify some cellular antigens on histological 
samples using specific antibody indirect markers of cellular proliferation. They are the tests 
that show concomitant presence of p16INK4a pathological cell protein overexpressed under the 
effect of the E7 HPV protein in samples containing only integrated forms of virus[103-104] 
and Ki-67 nuclear protein, only observable in cells in active proliferation[105-106].  
 
In fact, under normal conditions there is a concomitant expression of p16INK4a and Ki 67 
within a single cell; the contemporary expression of the two markers is indicative of the 
deregulation of cell cycle control and resulting state of cellular transformation[107]. 
 
Lastly GROUP 4 belong to the tests which thanks to the Fluorescence In Situ 
Hybridization (FISH) technique, are able to identify region amplification mapping the human 
telomerase gene in locus 26 of the long arm in chromosome 3 (3q26) present only in 
transformed cells and not in normal tissue[108-109]. The physiological role of the telomerase 
is to repair chromosome ends that with cellular aging tend to shorten, it follows that a number 
of copies equal to or greater than 5 (trisomies are para-physiological exhibits and 
quadrisomies could be due to the cell replication phase) represents a significant marker of 
CIN progression to carcinoma. Indeed telomerase hyperactivity that causes duplication tends 
to immortalize the infected cell, with an elevated progression from CIN to cancer and with 
reduced possibility of lesion spontaneous regression.[110-112] 
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 Marker Target Technology Test HPV Typing 
Full 
genome 
Signal  
amplification  
Assay 
digene HC2 HPV DNA Test 
 
Cervista®HPV HR 
NO 
 
NO 
 
GROUP 1 HPV DNA 
 
 
L1 
 
 
 
 
 
 
 
 
E1 
 
 
L1+E6/E7 
 
Target  
amplification 
 assay 
AMPLICOR®HPV 
 
Cobas4800®HPV 
 
Abbott RealTime High-Risk HPV 
 
LINEAR ARRAY® HPV 
 
CLART®HPV2 
 
 
Papillocheck® 
 
 
ProDect® CHIP HPV TYPING 
NO 
 
partial (HPV16 & HPV18) 
 
partial (HPV16 & HPV18) 
 
YES 
 
YES 
 
 
YES 
 
 
YES 
GROUP 2 HPV RNA E6/E7 
Target 
amplification 
assay 
Aptima ®HPV Assay 
 
PreTect HPV-Proofer 
NO 
 
YES 
GROUP 3 Protein p16/Ki-67    Immunostain CINtec
® Plus - 
GROUP 4 
chromosomal 
aneuploidies 
3q26 
       (FISH) oncoFISCH® - 
Tab. 3[23] Some of the IVD for screening cervical cancer and the diagnosis of HPV infection (partly taken from 
Schiffman 2011) 
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2. Scope of the research 
The overall objective of the research was to investigate the possibility of improving an 
IVD, the ProDect® Chip HPV Typing[113], once the diagnosis of Human Papillomavirus 
infection, expanding, the number of genotypes potentially detectable and updating it, 
comparing them to the latest knowledge about the molecular biology and persistence 
mechanisms due to some high-risk oncogenic genotypes. Both aspects are in fact substantial 
for a kit that will present itself as a screening test for cervical cancer in the near future with 
regards to the prophylactic strategies towards some genotypes carried out worldwide through 
systemic vaccination programs, and the need to verify the real oncological risk of some HPV 
types, so far, defined as medium or low risk, but within particular geographical, social or 
health conditions may express a higher oncogenicity. 
 
The molecular platform in question involves three phases: 1) total nucleic acid (DNA) 
extraction from the cervical-vaginal sample, 2) gene amplification by Multiplex polymerase 
chain reaction (PCR) with three pairs of biotinylated primers sequences directed on human β-
globin gene, L1 region and the HPV E6/E7 region, respectively [114], 3) detection of 
amplicons obtained, labeled with biotin, through reverse hybridization with specific probes. In 
fact in the appropriate conditions the amplifications are denaturing and hybridized with 
complementary probes adhering to a plastic support said biochip or simply chip; follows a 
colorimetric reaction, streptavidin-mediated, which leads to the formation of a brown 
precipitate at the reactive probe. Each positivity creates different designs on the biochip 
(patterns) that are captured by a reader, the ProDect® BCS Biochip Reader, analyzed and 
interpreted by a dedicated software that explicit the diagnostic implications related to the 
different results obtained, in a report [115-117]. 
 
Assuming that the bcs Biotech Srl (www.biocs.it) platform IVD ProDect® CHIP HPV 
TYPING[113] employs a biochip type 5x5, or with 25 positions available for the same 
number of probes, the aim of the research was to design, develop and validate a biochip type 
6x6, with 36 positions available for additional gene targets, hereinafter referred to as HPV 
CHIP PLUS, all details will be described in the results section. 
 
For this project it was necessary to deepen the basic knowledge of HPV molecular diagnostics 
and implement a series of technological innovations and procedures for the new biochip 
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preparation. An increased number of genotypes detected, genomic regions characterizable 
with equal genotypes at high oncogenic risk, and the cross reactions between similar gene 
target have been disposed of, minimizing the nonspecific, without reducing the new platform 
sensitivity. Sensitivity and specificity are, in fact, two reverse concepts and in a multi target 
system must strike a point of compromise, especially if the platform must have a high 
negative predictive value (NPV), which must be attributed, in a sample, with reasonable 
certainty negativity for HPV infection. 
 
The research was conducted in accordance to the: Directive 98/79/CE that indicates the 
criteria of the Conformité Européenne (CE Mark) for in Vitro Diagnostic Medical Devices 
(IVD)[118], UNI EN ISO 9001:2008 relating to quality management systems, UNI CEI EN 
ISO 13485:2012 relating to research and development of medical devices and UNI EN ISO 
14971: 2012, concerning the application of management risk to medical devices. 
 
The research validation step was designed, even though with reduced numbers, inspired 
by the European Commission Decision of 27 November 2009 amending Decision 
2002/364/CE on Common Technical Specifications (CTS) for in vitro diagnostic medical 
devices in which establishes the need to test, in parallel with the test already CE Mark, any 
new kit contemplating a number of negative samples, positive for the sought target and/or 
potential interfering with it, such as the commensal flora or other pathogens due to infection. 
 
The study was divided into three main phases in order to achieve the specific objectives 
and results reported below more extensively (Tab. 4). 
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Phase Specific Objective Activity Result 
I 
Ideation 6x6 chip 
with 36 positions 
available for the 
deposition of as 
many informative 
probes 
complementary to 
HPV sequences and 
human 
 
Design/verify HPV sequence  
 
System calibration for the 
spotting chip and acquisition 
patterns 
 
Probe calibration [ ] / Positive 
synthetic controls (PC) 
 
Verify and test chip 6x6 batches  
 
Check complete platform of cell 
lines 
 
Biochip 6x6 prototype, 36 dots  
 
Define standard spotting conditions 
/ reading software for 6X6 
 
 
Chip performance with PC 
 
 
Pre-tested batches to run search 
 
Performance platform complete 
with cell lines 
 
II 
Cloning HPV 
genomic sequences 
from clinical isolates 
(L1 - E6 / E7), 
acquisition WHO 
Standard 
 
Selection clinical samples HPV+ 
Cloning target sequences 
Check inserts 
 
Performance verification testing 
assays of cloned products from 
scratch and WHO standard 
 
18 cloned HPV: 
13 cloned HPV L1 with E6 / E7 
 5 cloned HPV L1 
 
Performance platform complete in 
detecting multiple sequences of 
cloned HPV and WHO standard 
 
III 
 
Preliminary 
validation of the 
diagnostic 
capabilities Test 
 
 
171 samples from Benin (Africa) 
 
Preliminary data regarding the 
Diagnostic Performance 
Tab. 4 - Articulation schematic research stages, objectives, activities and results 
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3. Materials and Methods 
3.1 Biochip preparation 
On a white polystyrene support, appropriately chemically modified (biochip), width the 
dimensions of a 96 well microplate, filed with aqueous oligonucleotide sequence solutions 
between 30-40 nucleotides (probes) in length, according to a precise pattern. Microdrops of 
these solutions, with sized and calibrated volumes, were deposited by means of a spotting 
machine (SCIENION AG Volmerstraße 7b D-12489 Berlin, Germany) equipped with a 
piezoelectric system[119], or an upright micro needle immersed in an electromagnetic field 
which reduces the phenomena of surface tension limiting the diffusion of each drop outside of 
the squares contours, constituting an ideal grid deposition, bounded in red (Fig. 10A-B), in 
which the black dots represent download areas, 36 in the present project. 
 
 
Fig. 8A Droplet from the needle 
 
Fig. 8B Grid positions on the chip probes 
                          
        
All HPV probes, covalently bound to the well, are designed to be complementary to 
specific L1 region sequences of the most prevalent high, medium and low HPV oncogenic 
risk for a total of 31 genotypes characterizable, and E6/E7 region sequences of the 3 major 
high and medium HPV oncogenic risk groups. On the two opposite grid corners, a probe 
placed in duplicate, reveals an internal sequence of the human β-globin gene, which acts as a 
process control region for the total DNA extraction of the original sample represented by the 
cervical-vaginal spatula. At the other two opposite corners, another probe called 
Hybridization Control, was designed to have no homology with human origin or viral 
infection sequences, and serves as a control for the physical-chemical conditions of the chip 
colorimetric assay detection. 
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3.2 Essay detection biochip 
The optimal concentration [ ] for each probe has been defined on the basis of the 
specific signal obtained by hybridizing, under appropriate stringency conditions, scalar 
concentrations of complementary nucleotide sequences to the various probes having a biotin 
molecule in the 5th position, referred to as the Positive Controls (PC), so as to detect the 
hybrid Probe: PC using traditional colorimetric methods, as shown schematically in Fig. 9. 
 
Briefly, 20 µl of a Tris EDTA solution at pH8 (TE pH8) of PC and 100µl of 
hybridization buffer are incubated for 1 hour at controlled temperature and shaking on the 
chip. After washing, followed by the addition of a Streptavidin Alkaline Phosphatase 
conjugated (AP) solution (30 'incubation at room temperature), which, after further washing,  
facilitation of the colorimetric reaction required for detection due to the addition of 5-bromo, 
4-chloro, 3-indolylphosphate (BCIP)/Nitro-Blue Tetrazolium (NBT) enzyme substrate for 15 
minutes at room temperature and obscured from light. The complementary sequence presence 
to the probe (PC) or the target in the original sample prior target amplification by Multiplex  
PCR is shown by the formation of a brown color precipitate (dot) corresponding to the  
relative specific probe. 
 
 
Fig. 9. Colormetric revelation, pattern analysis via ProDect® BCS Biochip Reader 
Hybridization 
PC
Colorimetric
revelation
Data analysis
Specific probes 
for the different 
targets
Chip preparation 
23 
 
3.3 Synthesis of oligonucleotides 
All oligonucleotide sequences used were designed based on the sequences deposited at 
the National Institute of Health (NIH Nucleotide GeneBank: 
http://www.ncbi.nlm.nih.gov/entrez/). Sequences with a > 90% homology degree, compared 
to all sequences reported for that region and in particularly for that HPV genotype in the 
database, have been synthesized by AB Applied Biosystems 3400 DNA Synthesizer 
multichannel system on columns to 1µM, desalted overnight in a 30% ammonium solution, 
and then purified by HPLC (Gilson 360) obtaining solutions with purity degrees of OD 
260:280 = 1.8-2.0 and an early one [ ] of 100 ng/µl. For the PC sequences were employed 
similar synthesis procedures, taking care to place them in 5th position, as a modified base, a 
biotin molecule. Starting from the stock to 100 ng/µl for Positive Controls were prepared 
scalar solutions of each one (2.5 ng/µl, 0.5 ng/µl, 0.125 ng/µl, 0.05 ng/µl, 0.0115 ng/µl, 
0.00125 ng/µl, 0.000125 ng/µl) which then were evaluated individually on all probes adhering 
to the biochip in order to verify the specificity and sensitivity of each probe and the set of 
probes deposited on the chip. After colorimetric detection on each chip was evident the 
specific signal expected and have been shown any signs of cross-hybridization with additional 
probes on the chip. For each probe was defined both the PC minimum detectable 
concentration and the PC maximum concentration which does not determine the occurrence 
of non-specific signals. 
 
3.4 Biochip reading system 
For the acquisition and analysis of the results or patterns that are formed on the chip as a 
result of the precipitation of the dye in correspondence to the reactive probes was an 
integrated platform ProDect® BCS Biochip Reader (bcs Biotech Srl). It is formed by a sliding 
carriage and two optical modules that moves on Cartesian axes XY, formed by reflecting lens 
and focusing, matched to the same number of the linear Charge Couple Device (CCD), that 
are independent and symmetrical. Through a process of controlled scanning by a Central 
Processing Unit (CPU), acquires the images in parallel and high resolution[116]. These are 
transmitted from an interface such as a USB port to a computer, where a software will 
reassemble them into a single image which is processed and analyzed with respect to 
predefined patterns of interpretation. 
 
24 
3.5 Molecular diagnosis 
3.5.1 Samples 
Amplified DNA extracted from cervical-vaginal spatulas were tested on the prototype 
biochip developed. All samples were exposed to previous molecular screenings for the 
detection of HPV with various CE Marked tests and/or sequencing for confirmation of the 
genotype, as well as cytological screening by PAP TEST. The degree of dysplasia was 
attributed according to the Bethesda classification 2001[120], namely: “atypical squamous 
cells” (ASC) subdivided in 1) ASC of “undetermined significance” (ASC-US), e 2) “cannot 
exclude high-grade squamous intraepithelial lesion” (ASC-H); “low-grade squamous 
intraepithelial lesion” (LSIL); “high-grade squamous intraepithelial lesion” (HSIL); 
“squamous cell carcinoma” (SCC); adenocarcinoma in situ (AIS); “atypical glandular cells” 
(AGC), the latter further classified into atypical "not otherwise specified" (AGC-NOS AGC-
NOS source endocervical, endometrial, or glandular) or probably neoplastic (AGC favor 
neoplastic origin endocervical or glandular). The amplifications were acquired by PCR 
multiplex with the ProDect® Chip HPV Typing kit (bcs Biotech Srl). In short, each reaction 
was performed in duplicate on a volume of 50 μl: 5 μl of the DNA extracted with the 
ProDect® HPV Extraction kit and 45 µl mixture containing KCl, Tris-HCl, MgCl2, Taq DNA 
polymerase, dNTPs, and three pairs of biotinylated primers. GP5+/GP6+ pair of primers  
amplified fragments of the 143 bp from the L1 region of HPV, the 1M/2R pairs of the E5/E7 
region from the HPV HR (whose target depending on the genotype vary from 233-268 bp) 
and the third pair of primers amplifying a sequence of 178 bp of the gene of the human β-
globin. PCR applied protocol, reagents and amplified storage conditions follow kit 
recommendations. Only one aliquot, after PCR, was used for the diagnosis on the 5x5 chip 
contained in the ProDect® Chip HPV Typing kit, the other one was stored at a -20°C 
controlled temperature to reduce degradation/fragmentation risk and it was used subsequently 
for the preliminary validation of 6x6 biochip in development, hereinafter referred to CHIP 
PLUS. This new platform used to reanalyzed 171 amplified obtained from African origin 
samples, already collected and studied in an International cooperation project funded by the 
Autonomous Region of Sardinia. The project was entitled Screening of human papilloma 
virus (HPV), and prevention of cervical cancer in women from city of Cotonou and Benin 
coordinated by the Department of Cytomorphology at the University of Cagliari in which bcs 
Biotech Srl participated as a partner [113]. All histological, cytological and molecular 
preliminary samples data, used in this research were received and processed by the 
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Cytomorphology Department of the University of Cagliari. The study protocol was approved 
by the local ethics committee of Benin and informed consent has been given to all parties in 
accordance with the World Medical Association, Declaration of Helsinki.  
 
In order to confirm, when possible, the results obtained with the ProDect® Chip HPV 
Typing [113], amplification products were also sequenced using the Big Dye Terminator 3.1 
kit (Applied Biosystems). The sequences were read on the ABI PRISM 3100-Avant 
sequencer (Applied Biosystems). 
 
 
3.5.2 ProDect® Chip HPV Typing (bcs Biotech S.r.l.) 
The data obtained by the new biochip were compared with those obtained using the 
ProDect® Chip HPV Typing Kit[113], IVD analogous method, which detects, besides the 
human β-globin gene as a control, 19 genotypes on the basis of the sequence of HPV L1 
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 6/11, 42, 43, 44) and some HPV at 
high-medium oncogenic risk[23] on the E6/E7 region, through a probes pool laid in a single 
dot. The different targets are amplified by Multiplex PCR. 5μl of total DNA extracted from 
biological samples are added to 45 μl of ready to use mix (1X PCR buffer set, 0.2 mM 
dNTP's, 2 mM MgCl2, and 2.5 U of Taq polymerase) also containing three pairs of primers: 
one complementary to the L1 region, one to E6/E7 region of high-medium oncogenic risk 
types and the last one to a human β-globin gene. Each amplification was also assessed by 
electrophoresis (80V - 48mA) on 2% agarose gel (Agarose, MP Biomedicals, Inc.) obtaining 
for each PCR reaction three different amplicons: 143 bp for the L1 region, 178 bp for the β-
globin and between 233-268 bp for the high-medium oncogenic risk types of E6/E7 region. 
At the end of the PCR, 20 μl of the amplified denatured are then dispensed in each well 
containing 100 μl of a Hybridization Buffer (80 μl) and Hybridization Control (20 μl)  
solution. Followed by 1 hour at 45°C in a shaking controlled incubation, then 3 biochip 
washes with 100 μl of Wash Buffer, at the end of which a solution is dispensed consisting of 
100 μl of Blocking Buffer 1X and 0.25 ml of streptavidin conjugated with an alkaline 
phosphatase (Strep-AP) for 30 minutes at room temperature. After another 3 washes 
proceeded with the addition of 100 μl of Revelation Buffer comprising chromogenic substrate 
(BCIP/NBT). Once an incubation for 15 minute at room temperature and protected from light, 
and a final wash, the test result is displayed on the well bottom which constitutes the biochip. 
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Indeed, the presence of any target sequence of the three primers pairs in the starting sample, is 
shown by the formation of a brown color dot in relation with the probe which has hybridized 
the complementary sequence to one or more amplicons between the three, which possibly 
formed during Multiplex PCR from each DNA. 
 
3.5.3 Digene® HC2 HPV DNA Test (Qiagen) 
The samples included in this study were also evaluated using Digene® HC2 HPV Test 
(Qiagen)[121-124] as the reference test, considered the gold standard for HPV infection 
primary screening. It is a signal amplification method in a liquid phase which starts to release 
total DNA contained in the biological sample by alkaline lysis and makes it suitable for 
hybridization with RNA complementary pool probes of 13 HR HPV types [pool HR: 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68] and 5 LR HPV types (LR pool: 6, 11, 42, 43 and 
44). RNA/DNA hybrid resulting are captured on the wells surface of a microtiter plate coated 
with specific hybrids antibodies. Follows disclosure with the same antibodies conjugated with 
alkaline phosphatase. Each antibody binds various molecules of alkaline phosphatase and 
more conjugated antibodies bind to each captured hybrid. The enzyme substrate addition 
mediate a chemiluminescent reaction; radiation is quantified in Relative Light Units (RLU). 
The emitted radiation intensity indicates DNA target presence or absence in the sample 
compared to a threshold value (cut off) related to suitable calibrators supplied with the test: to 
cut off  ≤1 sample is negative, to cut off >1 is positive for HPV DNA sequences. The test, 
however, lacks a compliance audit of sampling thus only owns calibrators feature test based 
to HPV positive controls with respect to which is assigned positivity/negativity signal, while 
no calibrator investigates the proper specimen collection in terms of quality and quantity. It is 
an analysis with high reproducibility even if the signal intensity that is obtained cannot be 
correlated with the viral load or the cytological lesion severity. The test is also not 
distinguishing between the different HPV genotypes, except between groups of oncogenic 
risk, cannot establish any co-infections between different types within the same group. 
 
3.6 Cell Lines  
Three cell lines[125-129] were purchased from ATCC/LGC catalog to verify the 
diagnostic capabilities of the complete platform, rather from the extraction phase: C-33 A 
(ATCC® CRM-HTB-31™), HeLa (ATCC® CRM-CCL-2™), Ca Ski (ATCC® CRL-1550™). Each line 
was propagated following the indication in the accompanying form provided. Scalar dilutions 
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with a 1:10 ratio of the various lines were prepared in a cytological transport medium (as 
ThinPrep®) in order to obtain, in principle, 106, 105, 104, 103, 102 and 10-1 cells/ml. From each 
dilution, and for each line, were extracted total DNAs, according to the ProDect® HPV 
Extraction kit (bcs Biotech Srl) protocol that exploits the osmotic cells lysis, protein digestion 
with Proteinase K and total DNA alcoholic precipitation, or according to the purification and 
elution column Qiamp DNA Mini Kit (QIAGEN) protocol. The extracted DNA was 
submitted to the diagnostic procedure listed in the ProDect® CHIP HPV TYPING (bcs 
Biotech Srl) kit protocol. All these lines were derived from uterine cervix carcinomas, 
however C33A cells are a line obtained and stabilized from a uterine cervix carcinoma 
negative for HPV DNA/RNA, Ca Ski contains about 600 copies of HPV-16 genomes per cell 
and Hela about 50 copies of HPV-18 genomes per cell. Using these numbers, conventionally, 
50 ng of DNA (about 1.5104 cell) extracted from Ca Ski and Hela cells contain circa 9 x 106 
copies of HPV16 and 7.5 x 105 copies of HPV18, respectively. It shows that the dilutions 
tested theoretically contains from 6108 to 600 total copies of HPV16 and from 7.5105 to 50 
total copies of HPV18, respectively. 
 
3.7 Cloning DNA HPV types with high and low oncogenic risk 
All clones, nominated BCS clones, were prepared in the bcs Biotech Srl confined area, 
authorized by the Ministry of Health for the production of Genetically Modified 
Microrganism (MOGM). Particularly in the context of this research, plasmid vectors were 
inserted into bacterial cultures of E.coli, containing a viral DNA amplified insert[130]. 5 μl of 
extracted DNA from positive samples for individual infections by ProDect® CHIP HPV 
TYPING kit were amplified with primers of the specific infected genotype. Primer pairs were 
designed with reference to the genotype sequences deposited at the National Institute of 
Health (NIH Nucleotide GeneBank: http://www.ncbi.nlm.nih.gov/entrez/), in order to obtain 
amplification products, and then inserts, where possible, > 3.0 KB for high-medium risk types 
which, clockwise, included from ORF L to ORF E6/E7 or for some low-risk types a > 300 bp 
region internal to the L1 sequence. Each amplification reaction contained: 0.5 μM of each 
primer, 1X PCR buffer set, 0.2 mM of dNTPs, 2 mM of MgCl2, and 2.5 U of Taq 
polymerase. Each amplified was assessed by electrophoresis (80 V-48 mA) on 2% agarose gel 
(Agarose, MP Biomedicals, Inc.). 1 μl of the amplification product was then cloned into a 
pCR2.1 plasmid vector of E.coli by TA Cloning® kit (Invitrogen Life Technologies). The 
Invitrogen technology relies on the ability of T4 DNA Ligase to mediate ligation between an 
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amplification product with cohesive ends (blunt end) and a pCR2.1 vector, with 
complementary and cohesive sites creating a larger insertable plasmid in competent E.coli 
cells. Following seeding in agar plates containing a selective differential medium, then 
bacterial colonies containing the plasmid with the desired insert, may be isolated and appear 
in translucent white compared to those containing only the vector without the amplified insert 
(Fig. 10). This screening method is called white/blue screening. The color difference is due to 
the gene LacZα in the recombinant colonies, present in the pCR2.1 vector, the interruption 
due to the amplified sequence insertion are no longer able to metabolize the galactose analog 
of X-Gal. 
 
 
 
 
 
 
 
 
 
Fig. 10. Colonies including or excluding the plasmid with the insert according to the white / blue screening 
method 
 
For the plasmid DNA purification was used the GenEluteTM HP Plasmid Miniprep Kit 
(Sigma-Aldrich). Each clone was quantified by spectrophotometer (Thermo Electron 
Corporation - Biomate3) after dilution 1: 400 (2.5 μl extract plasmid + 997.5 μl of TE). No. of 
copies/ µl of plasmid preparations has been calculated as follows: 
 
 
 
where PMi = is the number of bp in the insert 
     PMp = is the number of plasmide bp (pCR2.1 è di 3912 bp) 
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This formula was derived by mathematical treatment by the following formula: 
 
 
 
where: 
g/µl of extracted DNA = OD x f.d. x 50 x 10-9 
PM = (PMi + PMp)x2x330*  
NA° = 6 x 1023  
*weight takes into account that DNA is double-stranded and assumes the weight of a nucleotide equal to 330 
daltons 
° Avogadro's number = number of molecules contained in a mole 
 
The equivalent copies are calculable by multiplying the number of copies/μl *ml  
(1000) but in the case the clones, with the exception of the WHO clones, it was preferred to 
express the concentration [ ] in copies/μl. The isolated clones were evaluated by Restriction 
Endonuclease EcoRI and PstI (Roche Diagnostics) on 2% agarose gels and gene sequencing. 
For each clone a restriction map were designed using the reference sequences and Webcutter 
2.0 software. Once the expected sequence accuracy confirmed, a maxiprep or bacterial culture 
expansion and plasmid DNA extraction and purification containing at least 1010 copies/μl of 
target sequence for each clone was prepared. Besides the prepared clone by bcs Biotech, the 
HPV CHIP PLUS developed, was also evaluated using the Standard cloned HPV16 and 
HPV18 of the World Health Organization (WHO) prepared according to the guidelines given 
in the WHO Human Papillomavirus laboratory manual ed. 2009, arranged and distributed by 
the National Institute for Biological Standards and Control (NCBI) http://www.nibsc.org/. 
These standards, called henceforth WHO16 and WHO18 were diluted and manipulated as 
described in the accompanying form[131-132]. The ProDect® CHIP HPV TYPING amplified, 
under the External Quality Audits (EQA) of WHO HPV LabNet Global Reference Laboratory 
in 2011 distributed by Equalis AB[133] program were evaluated on CHIP HPV PLUS[134]. 
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4. Results 
Over three years, this research led to the development of a diagnostic system for 
innovative research for broad spectrum and molecular characterization of the main Human 
Papillomavirus infecting the anogenital area, potential etiologic agents alone, or in co-
infection among them, of preneoplastic and neoplastic lesions. In summary, the path in 
several stages brought: 
 
 design of the new chip, hereinafter referred to HPV CHIP PLUS, to be used in 
combination with the amplification mix of the ProDect® CHIP HPV TYPING[113], 
kit already CE marked, and promoted by bcs Biotech Srl for cervical cancer screening. 
This system currently types only 19 HPV genotypes and generally reveals the 
presence of E6/E7 sequences related to the virus at high-medium oncogenic risk (HR) 
represented by a single dot on the chip for this region. 
 
 the creation of a pre-series batches HPV CHIP PLUS prototype 
 
 verification of diagnostic capabilities using synthetic DNA targets (PC), cloned DNA, 
DNA extracted from immortalized cell lines and DNA amplification by cytology 
samples from women with different grading of cervical dysplasia, infected or not by 
HPV. 
 
Below description of the individual results and the evidence to support them. 
 
4.1 New HPV CHIP PLUS  
Specific genotype probes with HPV high anogenital tropism and for the major subtypes 
have been designed in order to realize a new prototype chip capable to typify on the basis of 
the L1 region sequence no.21 in high-medium oncogenic risk genotypes and no.10 low-risk 
types, alone or in co-infection between them, (HPV 6, HPV 11, HPV 16, HPV 18, HPV 26, 
HPV 30/40, HPV 31, HPV 33, HPV 35, HPV 39, HPV 42, HPV 43, HPV 44, HPV 45, HPV 
51, HPV 52, HPV 53, HPV 56, HPV 58, HPV 59, HPV 66, HPV 67, HPV 68, HPV 70/72, 
HPV 73, HPV 81, HPV 82, HPV61/CP6108) and at the same time to monitor the presence of 
sequences in the HPV E6/E7 region (always preserved even in the case of viral integration) of 
high-medium oncogenic risk types being able to discriminate them in three main groups: 
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E6/E7-HPV18/45, E6/E7- HPV33/52/58/56/66/67/82/59, E6/E7-HPV16/35/31. Three dots on 
the chip, in fact, represents a consensus of probes with different mixtures and/or 
specifications capable of reacting with the amplified E6/E7 region of the main HPV high-
medium oncogenic risk types involved in cervical carcinoma. The presence of a positivity in 
the chip for one or more of these dots, in the absence of a specific typing with direct probes 
on the L1 virus region highlight, anyway, the positivity of the sample for high-medium risk 
HPV and allows increased levels of attention on cytologic evaluation or patient follow-up. 
 
The complete prototype test, named ProDect® CHIP HPV TYPING PLUS, includes the 
necessary reagents to amplify and reveal via reverse hybridization for each sample: 
 
1. L1 region of 31 DNA HPV (typing region), 
 
2. E6/E7 region main high-medium oncogenic risk types (which highlights the presence 
even in the absence of a L1 region signal, guiding the user to one or more different risk 
groups) 
 
3. Human β-globin, essential in order to have complete control of the entire process 
(monitoring of any extractions performed in a non-suitable or substances inhibiting PCR). 
It is calibrated to obtain evident signals only in the case of clinical samples (levy) whit 
sufficient DNA for the virus detection (productive, latent or abortive infection). The 
amplification threshold/detection of human DNA corresponding to at least 105-106 
GenEqu/ml. 
 
The interpretation of the chip can be performed by naked eye (the dot are colored and 
their position is clear) or with by ProDect®BCS Biochip Reader whose software has been 
suitably adapted in the context of the present research to read a 6x6 pattern. The system is 
designed to establish, automatically and objectively, if the result that appears on the chip is 
valid or invalid based on the probes or pool positions as they were placed in the ideal 6x6 grid 
(Fig. 11). 
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Fig. 11 – The new CHIP HPV PLUS scheme: Probe positions with respects to their genetic targets 
 
A “VALID RESULT " can be due to different situations: 
 
1. Negative sample in the presence of a withdrawal/DNA conforms to the analysis, the 
chip has only 4 signals (dot) at the four corners: N° 2 dot for -globin gene, which acts 
as a control sequence for the monitoring of extraction/amplification and N° 2 dot 
relating to the hybridization control for the detection step monitoring (Fig. 12A). 
 
 
 
 
 
Fig. 12A – Negative sample 
 
2. Positive Sample when, in the presence of a levy/compliant DNA, on the chip another 
dot appears, over 4 concerning levy/DNA compliance, which indicate the presence of 
HPV DNA in the starting sample, be characterized on the basis of the L1 and/or E6/E7 
sequences. These dot can be single or multiple depending on the type of infection and 
from the different viral genotypes which support it (Fig. 12B). 
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Fig. 12B – Positive sample 
3. Positive Sample when, in the presence of a not conform specimen/DNA, chip presents 
2 hybridization control dot, one or more signals relating to sequences/HPV types, but 
not any dot related to the -globin (Fig. 12C). In this case the sample is positive even 
if the sample is incongruous (<105 GenEqu/ml), having evidently very high viral load. 
 
 
 
 
Fig. 12C - Positive sample 
In conditions of a valid result and sample positivity for HPV are expected similar 
pattern to those reported below, which schematize possible single or multiple infections, Fig. 
13. 
 
Note that the developed prototype chip, due to the probes mixture designed and placed 
in 3 chip different positions having as target the HR HPV E6/E7 region, is able to detect these 
genotypes presence in different conditions, or when: 
 
1) the ratio between HR HPV L1: E6/E7 copies number is much greater than 1, only L1 
region, with its virus typing, can be amplified and detected. 
 
2) is close to 1, it is possible to amplify and detect of both L1 region and E6/E7 region of 
the same virus or of different genotypes. 
 
3) the ratio between HR HPV L1: E6/E7 copies number is much less than 1, it has 
amplification and detection of the single E6/E7 region with the corresponding 
classification of risk group (Group HPV18/45, Group 16/35/31, Group 
HPV33/52/58/56/66/67/81/59) on which basis three E6/E7 probe groups react, 
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4) in the case of co-infection between LR HPV, which generally show productive benign 
infection always typable on the L1 region as HPV6 or HPV11, and HR HPV persistent 
or in already integrated form viruses (see examples in Fig. 13). 
 
The "INVALID result" can occur in different situations listed below. 
Lack of one or more controls. If the software is not able to detect the dots of the four 
corner related to the controls (2 Hybridization Control + 2 for -globin) it considers the 
outcome and the diagnostic test as "invalid". Positivity for only one point of each control 
affects the compliance of the test. The only exception might be made if the test presents 2 
hybridization control signals, but not the -globin ones, and one or more signals relating to 
sequences/HPV types. In this case the sample is certainly positive even if it is incongruous 
(<105GenEqu/ml) as the viral load is obviously high elevated (see example Fig. 12C). 
 
Negative Control Signal. A precipitate at the relative negative control dot shows an 
incorrect hybridization. It follows that a signal in this position must not be present in any type 
of result. If operator or reader displays its presence, result will be "invalid". The test is 
considered INVALID even in the case of positivity for HPV sequences (Fig. 12D). 
 
Signal attributable to identical HPV in all analyzed chips. The test is to be considered 
INVALID even in the case of the same attributable signal as the HPV probe is obvious in all 
samples, processed in parallel, in the same run. In this case the carry-over possibility exists or 
the dragging of the amplified HPV from one chip to another by the operator during the test 
execution. In this case the process needs to be restarted from the extract DNAs and repeat the 
session. 
 
 
 
 
Fig. 12D – Example of an invalid sample 
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Fig. 13 - Examples of positive patterns on the CHIP HPV PLUS 
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4.2 CHIP HPV PLUS Sensitivity and Specificity  
Eight preproduction batches of the new prototype CHIP HPV PLUS were prepared. 
Each one has been identified by a code and it has been evaluated separately from the other to 
verify the new chip performance and the variability between manufactured products at 
different times and with different probe batches in order to establish the method robustness 
also in relation to reliability requirements of the individual components, as required by the 
standard 98/79/CE for IVD.  
 
4.2.1 Synthetic DNA  
Evaluating chip sensitivity and specificity in detecting scalar concentrations of the 
Positive Controls (PC), synthetic complementary DNA to the probes immobilized on it, were 
highlighted by the following characteristics (Tab. 5): 
 
 an analytical sensitivity equal to 0.0115 ng/µl for each probe, meaning the minimum 
detectable amount of each PC for all deposited probes is <11.5 pg/µl, this is due to 
some probes being able to detect up to 0.00115 ng/µl (~1 pg ). 
 
 an analytical specificity equal to 97.53%, with a standard deviation equal to ± 0.37 and 
0.38% Variation Coefficient 
 
This specificity arises from a medium of all specific information obtained by the 
informative probes in the panel, testing PCs at an elevated concentration, equal to 2.5 ng/µl. 
Note that in the detection assay a further 20 µl of PC was added to the concentration of 2.5 
ng/µl, corresponding to ~50 ng total synthetic DNA single strand place to hybridize on each 
chip. This concentration was chosen in order to imitate an amount of HPV DNA target 
potentially high, comparable to that defined in the literature, to be contained in 50 ng of total 
DNA extracted from 1.5104 Ca Ski and HeLa cells, or 9 x 106 HPV 16 copies and 7.5 105 
HPV 18 copies, respectively. This assay condition was developed and put in to place to detect 
possible cross-reaction between probes and not complementary genotypic sequences. Indeed,  
in the case of high viral loads, an example referring to a single HPV type, any cross-reaction 
between probes would lead to an incorrect diagnosis of the sample, attributed to the presence 
of multiple signals, in multiple infections to a woman with an individual infection. Specificity 
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increases, 99.65%, for PC concentrations equal to 0.5 ng/µl, theoretically corresponding to 
containing ~10 ng of total DNA, if derived from Ca Ski ~1.8 x 106 copies of HPV 16 and 1.5 
x 105 copies of HPV 18 if derived from HeLa cells, respectively. 
 
Batch CHIP HPV PLUS Analytical Sensibility Analytical Specificity PC 2.5 ng/ µl 
Analytical Specificity 
PC 0.5 ng/ µl 
12132 0.0115 ng/ µl 97,44 99,8 
11234 0.0115 ng/ µl 98,32 100 
12136 0.0115 ng/ µl 97,22 99,2 
12137 0.0115 ng/ µl 97,22 99,2 
12138 0.0115 ng/ µl 97,29 99,5 
12144 0.0115 ng/ µl 97,36 99,5 
12145 0.0115 ng/ µl 97,73 100 
12146 0.0115 ng/ µl 97,66 100 
Media 0.0115 ng/ µl 97.53 99.65 
DS - 0.37 0.32 
C.V. - 0.38% 0.32% 
  Tab. 5 Analytical performance from different CHIP HPV PLUS lots using PC 
 
4.2.2 DNA extracted from cell lines 
The complete diagnostic platform, denominated ProDect® CHIP HPV TYPING PLUS, 
has been verified on cell lines using 8 pre-series batches of CHIP HPV PLUS product in 
combination with as many number of primer mix as batches. As shown in Tab. 6, C33A cells, 
HPV-uninfected, for dilutions with low cellularity <104 cells/ml (103-102-10 cells/ml) result 
as "invalid" samples, i.e. for all 8 batch chips, the DNA extracted, amplified and detected on 
the C33A chip, did not show a corresponding dot to the human β-globin. This conditional test 
is designed and implemented to alert the user when the test is not running a significant and 
sufficient amount of total DNA. This limit of the minimum necessary cells to assign a levy 
compliance takes into account different forms of HPV infection (productive, latent, abortive). 
Indeed samples with a fair amount of cells, i.e. ~105-106 cells/ml, are more representative of 
the cytological situation but especially allow greater statistical probability of virus detection 
in its more subtle forms (latent and integrated). When the same dilutions of C33A cells (103-
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102-10 cells/ml) were evaluated on Hybrid Capture® 2 (HC2) HPV Test platform they were 
defined as negative. Note, however, that in this type of test there is no levy compliance check, 
or minimum start sample cellularity; the negativity diagnosis are attributable to the HPV 
sequences absence and not to the fair amount of collected and subjected to lysis material. 
ProDect® CHIP HPV TYPING PLUS platform, when tested using the HPV infected cell 
lines, detected viral sequences with the same diagnostic sensitivity and specificity with 
regards to the Hybrid Capture® 2 (HC2) HPV Test. No cross reaction (non-specific) 
occurrence was also detected with the extract containing 106 cells/ml both in the Ca Ski cells 
than on HeLa, while HPV sequences (both the L1 region of HPV-16, as well as the 
E6/E7region) were detectable in extracted DNA, theoretically from a dilution with a single Ca 
Ski cell with 10-100 HeLa cells (assumed that one Ca Ski cell contains 600 genomes of 
HPV16 and 1 HeLa cell 50 genomes of HPV18). When cells same dilutions were evaluated 
on Hybrid Capture® 2 (HC2) HPV test platform, reproducible positive signals were obtained 
with DNA extracted from at least 10 Ca Ski cells or 10 HeLa cells. The diagnostic sensitivity 
of this platform was then 6000 and 500 supposed genomes of HPV-16 and HPV-18, 
respectively. Some examples of biochips detection of DNA extracted from these cell lines 
(Fig. 14). 
 
ProDect®CHIP HPV TYPING PLUS 
Line  Sensitivity cells/ml Result Copies/ µl  
C33A <104 Not Valid 0 
C33A >104 Negative 0 
Ca Ski 1 Positive HPV16 600 
HeLa 10 Positive HPV18  500 
Hybrid Capture ® 2 (HC2) HPV Test 
Line  Sensitivity cells/ml Result  Copies/ µl  
C33A <104 Negative 0 
C33A >104 Negative 0 
Ca Ski 10 Positive HPV HR 6000 
HeLa 10 Positive HPV HR   500 
Tab. 6 The analytical performance of the different CHIP PLUS HPV lots using lines C33A, CaSki, Hela 
     
39 
 
 
 
Fig. 14. In the biochip C33A cells superior (105/ml) HPV result negative, note the only points of conformity of 
the samples and the test. 
In the biochip Ca Ski cells inferior (105 cells/ml) HPV16 result positive, note the positivity for the region 
corresponding to the type HPV16 L1 and for the region E6/E7 corresponding to the high-risk group E6/E7-
HPV16/35/31 
 
4.2.3 HPV cloned DNA at high and low oncogenic risk 
In this research context 18 plasmids containing viral DNA sequences of variable size 
were prepared, formed by as many clinical specimens HPV types (Tab. 7). 13 of 18 
genotypes, including 11 HR-HPV, inserts above 3Kb comprising regions L1, URR, E6 and 
E7 were obtained. At the basis of this activity is the need to have available unlimited 
quantities of double-stranded DNA of high molecular weight similar to viral genomes found 
in real samples, these are to be used as additional controls for calibration of the amplification 
conditions  and detection of multiple different gene targets test: L1 and E6/E7 regions of HPV 
and human β-globin. After checking the accuracy of each insert sequence, DNA clone 
dilutions in TE were tested undiluted or with the addition of ThinPrep®Cytolyt Solution 
(Hologic) preservatives solutions containing a [ ] of C33A cells equal to 105-106 cells/ml, in 
order to check sensitivity and specificity of similar calibrators of the diagnostic system for the 
quantity and quality of the biological samples. The assays were performed in parallel using 
the HPV-16 and HPV-18 WHO standards, whereby [ ] is expressed in International Units (IU) 
or Equivalents Genomes (GenEqu). As analytical sensitivity was shown detection limit of 
each control corresponding to its minimum concentration on the specific probe (Tab. 8). In 
many cases, the detection threshold was expressed as interval and not as absolute number 
considered that cloned title, or No. copies/µl was measured by spectrophotometric reading 
(which is then considered margin of error). Reported sensitivity refer to both L1 and E6/E7 
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genetic targets and represent the minimum amount of copies/µl or IU/ML of cloned detected 
in 100% of the 24 tests carried out for each scale (Fig. 15). Some cloned scales were also 
tested on the Hybrid Capture® 2 (HC2) HPV reference method, which does not employ gene 
target amplification (Tab. 9). As expected, a greater amount of HPV DNA target is needed  
for a positive signal by Hybrid Capture® 2 (HC2) HPV Test compared to the ProDect® CHIP 
HPV TYPING PLUS. Note that ProDect® CHIP HPV TYPING PLUS, reveals two gene 
sequences of HPV genome for all HR clones tested, confirming both HPV genotype and the 
belonging group with respect to the E6/E7sequence, while Hybrid Capture® 2 (HC2) HPV 
Test defines only positivity for HPV HR cutoff > 1. 
 
The analytical specificity was calculated using samples obtained by mixing high titer 
clones with one or more low titer clones with 106 GenEqu/mL of C33A cells, referring to the 
threshold analytical sensitivity of each genotype, in order to evaluate at the gene amplification 
level and detection on the chip, inhibitions or higher affinity of the platform for some 
genotypes than others in the case of co-infection. In fact, a Multiplex PCR can arise 
interference phenomena between one or more genotypes[132]. As demonstrated by some 
examples below (Fig. 16) all HPV expected sequences, regardless of the clones mixed 
between them, if they were above the test detection limit, they were found on the new chip; 
different genotypes were correctly classified on the basis of L1 region direct probes. No 
cross-reaction was highlighted with genome sequences belonging to viruses, bacteria, fungi or 
protozoa often present in the female genital tract. (Tab. 10). 
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Tab. 7 HPV sequences cloned list and insert size achievable with specific HPV type primers 
HPV type ORFs Genebank Accession Number PCR product 
6 L1 AF092932.1 426 bp 
11 L1 M14119.1 448 bp 
16 L1- E6/E7 K02718.1 3532 bp 
18 L1- E6/E7 X05015.1 3647 bp 
30 L1- E6/E7 X74474.1 3641 bp 
31 L1- E6/E7 J04353.1 3523 bp 
35 L1- E6/E7 M74117.1 3427 bp 
42 L1- E6/E7 M73236.1 3394 bp 
45 L1- E6/E7 X74479.1 3500 bp 
51 L1- E6/E7 M62877.1 3535 bp 
52 L1- E6/E7 X74481.1 3064 bp 
56 L1- E6/E7 X74483.1 3554 bp 
58 L1- E6/E7 D90400.1 3585 bp 
59 L1- E6/E7 X77858.1 3544 bp 
66 L1 U31794.1 448 bp 
70 L1 U21941.1 454 bp 
73 L1- E6/E7 X94165.1 3474 bp 
81 L1 AJ620209.1 450 bp 
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ProDect® CHIP HPV TYPING PLUS 
Sensitivity copies/μl  
Clone#lot 
 
Stock copies/μl reg.L1 reg.E6/E7 
HPV16#01A 6.91010 69-690 69-690 
HPV18#03A 2.81010 28-280 2800 
HPV45#05 2.0 1010 2000 200000 
HPV6#02 1.0 1011 100-1000 ND 
HPV11#01 1.3 1011 130-1300 ND 
HPV35#19A 4.7 1010 5-10 500-1000 
HPV31#09A 2.4 1010 1-5104 240 
HPV73#02A 3.3 1010 33-330 ND 
HPV51#08 4.6 1010 4800 10000 
HPV56#01A 5.0 1010 5-50 50000 
HPV59#11Al 1.0 1010 10000 100000 
HPV52#09 6.9 1010 6900- 69000 6.9-69 
HPV58#11 9.61010 9600- 96000 9.6- 960 
HPV66#02 1.3 1011 10000 ND 
HPV81#03 7.7 1010 100-770 ND 
HPV70#03 1.0 1011 100-1000 ND 
Clone#lot Stock UI/ML Sensitivity UI/ML 
WHO HPV16 107 102 5103 
WHO HPV18 107 103 104 
Tab. 8 Test sensitivity of new kit with the bcs Biotech S.r.l cloned and WHO standards 
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Hybrid Capture ® 2 (HC2) HPV 
Clone#lot Stock copie/μl Sensitivity copies/μl 
HPV16#01A 6.91010 1-3.5 104 
HPV18#03A 2.81010 2.8-7 104 
HPV35#19A 4.7 1010 4.7 104-105 
Clone#lot Stock UI/ML Sensitivity UI/ML 
WHO HPV16 107 1.5104 
WHO HPV18 107 3104 
 Tab. 9 Sensitivity of the reference test with some cloned bcs Biotech S.r.l and WHO standards 
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Fig. 15 Example of analytical sensitivity batch n° HPV CHIP PLUS 12144 assessed scale cloned HPV16 BCS 
6.9 106 copies/μl 
 
 
6.9 105 copies/μl 
 
 
 
6.9 104 copies/μl 
 
 
 
6.9 103 copies/μl 
 
 
 
6.9 102 copies/μl 
 
 
69 copies/μl
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Organism 
Acinetobacter  Neisseria gonorrhoeae Chlamydia tracomatis 
Klebsiella pneumoniae Gardnella vaginalis Candida albicans 
Bacteroides fragilis Mobilincus curtisii Tricomonas vaginalis 
Bacteroides ureolyticus Enterococcus faecalis Herpes simplex virus 1 
Bifidobacterium spp Escherichia coli Herpes simplex virus 2 
Lactobacillus spp Staphylococcus aureus Cytomegalovirus 
Mycoplasma hominis Streptococcus agalactiae Adenovirus 
Mycoplasma genitalium Corynebacterium spp Staphilococcus epidermidis 
Tab. 10 List of microorganisms that potentially could interfere 
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Clones: copies/μl Clones: copies/μl Observation 
HPV59: 108          + HPV16: 103 
 
HPV59: 108          + HPV18: 104 
 
HPV59: 108          + HPV35: 104 , HPV45: 104, HPV56: 104 
 
HPV18: 108                + HPV11:                                             
 1.3 108          
 
 
                           1.3 106          
 
 
                           1.3 104          
 
 
                           1.3 102          
 
HPV16: 108          + HPV59:  
                             108          
 
 
                             106               
 
 
                             104          
 
 
                             102               
 
Fig. 16. Examples of cloned mixtures to mimic co-infections between the various HPV types with a high number 
of copies close to the detection threshold of the test 
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4.2.4 Extracted DNA from cytological samples  
A preliminary assessment of the platform diagnostic performance was made on a total  
number of 171 amplified cytology specimens (Appendix - List 1) collected in Benin, Africa 
between 2009-2012 under the cooperation International project funded by the Autonomous 
Region of Sardinia, directed by Prof. Paola Sirigu, with the cooperation of  bcs Biotech as a 
partner. Analyzed samples of PAP TESTs undertaken resulted with a normal cytological 
status of 68.4% (117), while 31.5% (54) had morphological alterations with variable 
gradation (Tab. 10), with a prevalence of high grade dysplasia among women aged between 
30 and 50 years (Fig. 17). 
Cytology  Age range Total 
  15-25 25-35 35-45 45-55 55-65   
Normal 14 29 33 28 13 117 
LSIL 1 1 0 0 0 2 
ASCUS  5 14 9 4 1 33 
ASC-H 0 3 1 2 0 6 
HSIL 0 1 4 1 0 6 
AGC 0 0 4 2 0 6 
SSC 0 1 0 0 0 1 
Total  20 49 51 37 14 171 
Tab. 11 Distribution of samples with respect to age and cytology 
 
 
Fig. 17 Prevalence of dysplasia by age in the population sample analyzed 
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All samples were screened for HPV sequences using IVD ProDect® CHIP HPV 
TYPING kit, Hybrid Capture® 2 (HC2) HPV Test as a reference method and the ProDect® 
CHIP HPV TYPING PLUS platform under development. 
 
The following data refer to the infection detection ability by the three kits with two 
different approaches: 
 
 limit HPV types common to all three tests (Tab. 12A, 13A, 14A) 
 
 with reference to the ability to attribute sample negativity/positivity for HPV 
infection, compared to HPV circulating globally in the analyzed population 
(Tab. 12B, 13B, 14B). 
 
Limiting performance evaluation test only to common HPV types (18 genotypes 
detected by the probes pool of Hybrid Capture® 2 (HC2) HPV Test, and only to the positively 
infected samples by HPV HR: 16, 18, 31 , 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, and LR 
HPV 6, 11, 42, 43 and 44) test on chip showed high indices of correlation with the reference 
test, Hybrid Capture® 2 (HC2) HPV Test, demonstrating comparable performance. 
 
ProDect® CHIP HPV TYPING presents a Concordance Index (CI) by the reference 
standard method for sharing HPV types of 97.6% (167/171), a diagnostic sensitivity of 100% 
(64/64 agree) and a specificity of 96.2% (Tab. 12A). 
 
ProDect® CHIP HPV TYPING PLUS prototype showed a Concordance Index (CI) by 
the reference standard method for sharing types of 98.8% (169/171), a diagnostic sensitivity 
of 100% (64/64 agree) and a specificity of 98.1% (Tab. 13A). 
 
Obviously the correlation between the tests on CHIP, ProDect® CHIP HPV TYPING 
and ProDect® CHIP HPV TYPING PLUS is even higher,  with reference to the common HPV 
sequences (19 genotypes detectable HPV HR: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68, 73 - LR HPV: 6, 11, 42, 43 and 44, and HPV E6/E7) equal to CI = 73 + 97/171x100 = 
99.4%, (Tab. 14A). 
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 Hybrid Capture® 2 (HC2) HPV Test Total
ProDect® CHIP HPV TYPING + -  
+ 64 4 68 
- 0 103 103 
Total 64 107 171 
Tab. 12A. Screening samples for 18 common types of HPV, ProDect®CHIP HPV TYPING vs Hybrid Capture ® 
2 (HC2) HPV Test 
 
 Hybrid Capture® 2 (HC2) HPV Test Total
ProDect® CHIP HPV TYPING PLUS + -  
+ 64 2 66 
- 0 105 105 
Total 64 107 171 
Tab. 13A Screening samples for 18 common types of HPV, HPV ProDect® CHIP TYPING PLUS vs Hybrid 
Capture 2 (HC2) HPV Test 
 
 ProDect® CHIP HPV TYPING PLUS Total
ProDect® CHIP HPV TYPING + -  
+ 73 1 74 
- 0 97 97 
Total 73 98 171 
Tab. 14A Screening samples for 19 common types of HPV and region E6 / E7, ProDect® CHIP HPV TYPING 
PLUS vs ProDect® CHIP HPV TYPING 
 
For all three tests parting from data contingency table, the Cohen's Kappa was 
calculated, using as a reference the interpretation guidelines that define each K value a 
different concordance grading between tests (K <0.2 = poor concordance; 0.21<K<0.40 = 
modest concordance, 0.41<K<0.60 = moderate; 0.61<K<0.80 = good; K> 0.81 = excellent). 
 
All comparison between tests showed an excellent correlation (0.95 < Cohen's Kappa < 
0.97). However, analyzing the sample on the basis of all positivity detected, and then expands 
the number of genotypes to be considered as actually circulating in the population, a number 
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of negative samples highlighted with the reference methods, are, instead, positive for HPV 
infection with the new prototype ProDect® CHIP HPV TYPING PLUS, even if the correlation 
between the various tests is still good or excellent (0.79 < Cohen's Kappa <0.89). 
 
In light of such evidence, re-evaluating the ability of the different tests to diagnose HPV 
infection in the analyzed population, independently of its genotype, shows that:  
 
 ProDect®  CHIP HPV  TYPING presents a concordance index (CI) compared to the 
standard reference molecular method Hybrid Capture® 2 (HC2) HPV Test of 94%, CI 
(161/171), a diagnostic specificity of 90.6% (97/107 coincident negative) and a diagnostic 
sensitivity of 100% (64/64 coincident positive). In particular, the IVD chip, employing the 
pattern 5x5, revealed 10 further positive samples classified as negative by Hybrid 
Capture® 2 (HC2) HPV Test, including 3 with positive PAP TEST (3 ASCUS) and 7 with 
apparently normal cytology , (Tab. 12B). Cohen's Kappa is equal to 0.875. 
 
 Hybrid Capture® 2 (HC2) HPV Test Total
ProDect® CHIP HPV TYPING + -  
+ 64 10 74 
- 0 97 97 
Total 64 107 171 
Tab. 12B. Screening infection: ProDect®CHIP HPV TYPING vs Hybrid Capture ® 2 (HC2) HPV Test 
 
 Concordance Index between ProDect® CHIP HPV TYPING PLUS and the reference 
standard method Hybrid Capture® 2 (HC2) HPV Test was equal to 90% (154/171 
concordant). In fact, 17 samples were classified as positive by the prototype; of these, 
4/17 had a positive PAP TEST (1 HSIL-carcinoma and 3 ASCUS) and 8/17 showed 
positivity related to HPV genotypes cannot be classified by the Hybrid Capture® 2 (HC2) 
HPV Test without  the specific probes, (Tab. 13B). Cohen's Kappa is equal to 0.79. 
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 Hybrid Capture ® 2 (HC2) HPV Test Total
ProDect®CHIP HPV TYPING PLUS + -  
+ 64 17 81 
- 0 90 90 
Total 64 107 171 
Tab. 13B Screening infection: ProDect® CHIP HPV TYPING PLUS vs Hybrid Capture ® 2 (HC2) HPV Test 
 
 Concordance Index between ProDect® CHIP HPV TYPING and ProDect®CHIP HPV 
TYPING PLUS in development was 95% (162/171 concordant). Also in this case 8/8 
samples assigned as positive from the prototype showed HPV types undetectable by the 
IVD test without the specific probes (Tab. 14B). Cohen's Kappa is equal to 0.89. 
 
 ProDect®CHIP HPV TYPING PLUS Total
ProDect®CHIP HPV TYPING + -  
+ 73 1 74 
- 8 89 97 
Total 81 90 171 
Tab. 14B Screening infection: ProDect® CHIP HPV TYPING PLUS vs ProDect®CHIP HPV TYPING 
 
Given the reduced sample size of the population, and being impossible to attribute 
sample positivity with the certainty on the basis of the full-blown disease, from the moment 
that an infection can occur, even in the presence of a normal cytologic condition, and could 
not rule out other HPVs circulating in the population that were not included among the 31 
types detected by the prototype, individual platform performances, comparisons between tests 
were calculated at a confidence interval of 95%, according to the below exemplified formula 
and considering healthy negative and some infected samples resulting with at least two of the 
three methodologies used. We proceeded to consider a total of 89 samples as negative, 
including 76 normal, 13 seemingly pathological (1 HSIL, 1AGC, 2 ASCH, 9 ASCUS) by 
PAP TEST  and 82 samples as positive of which 41 apparently with a normal PAP TEST. All 
positives were confirmed by gene primers specific amplification followed by reverse 
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hybridization with specific probes and/or sequencing. For each kit were calculated the 
diagnostic performance (Tab. 15,16,17). 
 
 
 
 
 
 
 
 
Formula for calculating Confidence Interval of 95% 
 
 
   Infected     Healthy
Positive  a: 64  b: 0 
  Negative  c: 18  d: 89 
True Positive  64 a   
False Positive  0 b   
True Negative  89 d   
False Negative  18 c   
Total Samples  171a+b+c+d  
Sensitivity (SE) + 0.064 (IC95)   0,7805a/(a+c)  
Specificity (SP)   1,0000d/(b+d)  
Prev. POS. Values (VPP) 1,0000a/(a+b)  
Prev. NEG. Values (VPN) 0,8318d/(c+d)  
Tab. 15 Hybrid Capture ® 2 (HC2) HPV Test performance 
 
Sensibility Standard error 
Sample 
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   Infected     Healthy
  Positive a: 74   b: 0 
Negative c: 8   d: 89 
True Positive  74 a   
False Positive  0 b   
True Negative  89 d   
False Negative  8 c   
Total Samples  171 a+b+c+d  
Sensitivity (SE) + 0.064 (IC95)   0,9024a/(a+c)  
Specificity (SP)   1,0000d/(b+d)  
Prev. POS. Values (VPP) 1,0000a/(a+b)  
Prev. NEG. Values (VPN) 0,9175d/(c+d)  
Tab. 16 ProDect®CHIP HPV TYPING performance 
 
 
 
   Infected     Healthy
  Positive a: 81  b: 0 
  Negative c: 1  d: 89 
True Positive   81 a   
False Positive  0 b   
True Negative  89 d   
False Negative  1 c   
Total Samples  171 a+b+c+d  
Sensitivity (SE) + 0.033 (IC95)   0,9878a/(a+c)  
Specificity (SP)   1,0000d/(b+d)  
Prev. POS. Values (VPP) 1,0000a/(a+b)  
Prev. NEG. Values (VPN) 0,9889d/(c+d)  
Tab. 17 ProDect® CHIP HPV TYPING PLUS performance 
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Performance calculated in this way means, therefore, the capacity of the individual tests 
to evaluate the actual biological sample negativity for HPV sequences (Tab. 18) refer to 31 
genotypes classified by the prototype HPV ProDect® CHIP HPV TYPING PLUS, able to 
detect a further 14 and 13 genotypes respectively, with regards to those identified by the 
Hybrid Capture® 2 (HC2) HPV Test and with ProDect® CHIP HPV TYPING.  
 
Note that in the analyzed population, there is a strong prevalence of HPV that 
fluctuates, depending on the test used for screening, between 25% for the Hybrid Capture® 2 
(HC2) HPV Test and 47% for the ProDect® CHIP HPV TYPING PLUS in development (Fig. 
18A, B, C). In a sample like this, given the high probability of finding HPV sequences, high 
prevalence of infection enhance the positive predictive value of all tests. 
 
Performance of 31 HPV types 
Diagnostic 
Sensitivity 
IC95 
Diagnostic 
Specificity 
IC95 
K PPV NPV 
Hybrid Capture ® 2 (HC2) HPV Test 78.0% 100% 0.78 100% 83.0% 
ProDect® CHIP HPV TYPING 90.2% 100% 0.90 100% 91.7% 
ProDect® CHIP HPV TYPING PLUS 98.7% 100% 0.98 100% 98.8% 
Tab. 18 Summary of the performance tests used for screening the same population 
 
A.  
Hybrid Capture II (HC2) 
DNA TEST 
B. ProDect CHIP HPV TYPING 
PLUS 
C. ProDect CHIP HPV TYPING 
Negat i ve
75%
Posi t i ve
25%
Negat i ve
53%
Posi t i ve
47% Negat i ve
57%
Posi t i ve
43%
Fig. 18A,B,C Prevalence of apparent HPV infection in the population as a part of the screening test  
 
Sample analysis by screening Hybrid Capture® 2 (HC2) HPV Test , widely used in all 
world for its practicality, in this study divides the population of HPV-infected samples into 
three subgroups: those infected with HR HPV, those with LR HPV, and those with an 
apparently sustained HPV infection at high and low risk, HR + LR (Fig. 19).  
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It should be noted that this test does not perform the individual genotypes 
characterization, but attributes sample positivity compared to the two major risk groups: a HR 
positivity indicates sample positivity for one or more high-risk HPV oncogenic types between 
13 HR whose probes are contained in the test (HPV16, 18, 31, 33, 35 ,39 ,45, 51, 52, 56, 58, 
59, 68), while LR positive is an infection index  for one or more low risk types that  can be 
detect by the test (HPV6, 11, 42, 43, 44). 
 
It follows that the only detectable multiple infections are potentially the result of co-
infections between HR HPV and LR HPV. For infections caused by HR or LR cannot be 
established without further testing, whether it is a single or multiple infections. 
 
 
Fig. 19 Analysis of positive samples by type of infection with Hybrid Capture ® 2 (HC2) HPV Test 
 
The population samples analyzed utilizes the chip, and therefore typifies contextually 
the genotypes in different ways, these may be divided into two subgroups (Fig. 20), i.e. 
samples with single infections and those with multiple infections, involved in most cases 2 or 
3 viral types but, in some cases, also 5 different types (Fig. 21A & 21B). 
 
The amount of co-infections detected increases if the analysis is performed by ProDect® 
CHIP HPV TYPING PLUS kit in development due to the greater number of genotypes 
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characterized by the test and not due to cross-reaction occurrences between probes, excluded 
in the earlier stages of calibration test . 
 
Fig. 20 Analysis of positive samples by infection type with HPV ProDect® CHIP TYPING (CHIP) and the 
ProDect® CHIP HPV TYPING PLUS (CHIP PLUS) 
 
A B  
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Fig. 21 Single and multiple infections detected with ProDect® CHIP HPV TYPING (A) and with ProDect® 
CHIP HPV TYPING PLUS (B) 
 
Employing the ProDect® CHIP HPV TYPING  the predominance of high-risk types 
compared to low risk was 70% when calculated on observed positivity (Figure 22); the most 
frequent in absolute value (type/total positivity) and in decreasing order are types: HPV-16 
(15/103), HPV59 (14/103), HPV18 (10/103), HPV35 (8/103) and HPV58 (8/103). Some viral 
types, such as HPV-16, support in equal measure both single and multiple infections, however 
other genotypes are found almost exclusively in single infections, as HPV56 and HPV31, or 
vice versa prevail only in co-infection with others, such as HPV33 and HPV45. 
 
In 19% of infections it was observed that individual E6/E7 sequences attributable to 
non-typable virus and that by sequencing and the new HPV CHIP PLUS developed were 
connected to the genotypes HPV16 (5 of 11 cases), HPV52 (3/11) and HPV35 (3/11). The 
positivity for the E6/E7 region in absolute values for the HR HPV constitutes 10% (11/103) 
of the positive signals and refer to sequences of high HPV oncogenic risk evidently not 
typable easily by the different tests. It is worth noting that, Hybrid Capture® 2 (HC2) HPV 
Test did not detect 6 of the 11 HPV positivities of these samples and 5 of the 11 cases were  
in agreement to the presence of HR HPV. 
 
In multiple infections, instead, prevalent genotype is HPV35 followed by HPV16, 
HPV59 and HPV45 (Fig. 23). 
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Fig. 22 HPV genotypes detected with ProDect®CHIP HPV TYPING  
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Fig. 23 Prevalence of HPV types detected with ProDect® CHIP HPV TYPING - single and multiple infections 
 
The same population analyzed with ProDect®CHIP HPV TYPING PLUS substantially 
confirms the positivity observed even with the ProDect® CHIP HPV TYPING, but having a 
greater number of probes, features a number of types and viral sequences not discriminable 
with the other test , shown as a row columns in Fig. 24A-B. 
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Fig. 24A All HPV genotypes detected with ProDect® CHIP HPV TYPING PLUS in the population 
 
 
Fig. 24B Particular genotypes / HPV sequences not characterized by ProDect® CHIP HPV TYPING 
  
Among these, the numerically relevant are positive for the HPV81 type and the pool  of 
probes that detect HPV30 and HPV40 were however, not able to distinguish them. At the 
moment it is considered low-risk oncogenic genotypes. 
 
Significantly, from the point of view of a diagnostic and prognostic value of test, even 
the data obtained from a single DNA sample analyzed resulted as a carcinoma (SCC-HSIL) 
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by PAP Test, belonging to a woman of 27 years (ID004TG), negative with others tests 
employed, result, instead, positive for HPV82 and HPV66 by ProDect® CHIP HPV TYPING 
PLUS analysis, where, above all the type 82 is now considered a high oncogenic risk while 66 
types as medium risk. 
 
It should be highlighted that the probes in the ProDect® CHIP HPV TYPING PLUS for 
HPV6 and HPV11 occupy distinct positions on the chip and has allowed the positivity 
allocation and more specifically for the two genotypes. 
 
In particular, the four patients presenting prior positivity to infection with HPV6/11 
with ProDect® CHIP HPV TYPING, and treated by warts cauterization, to 2012 follow-up  
showed altered cytologic state  (Tab. 19) and still positive for HPV6 (3/4) and HPV11 (1/4). 
 
Sample ID Age PAP Test HPV 
48 HO 24 LSIL HPV6 
26 PN 37 ASCUS HPV6 
2012.001LK 42 HSIL HPV6 
2012.155SL 26 ASCUS HPV11 
Tab. 19 Follow up of some cases treated for condyloma 
 
From the above explanation it is evident that the HPV epidemiology is strongly 
conditioned by the screening test used. In fact, with the ProDect® CHIP HPV TYPING PLUS 
the number of infections caused by a single genotype is drastically reduced compared to 
ProDect® CHIP HPV TYPING (31 versus 54). In this type of infection, the prevalent 
genotype is HPV52, followed by HPV6, while 19% of positivity is attributable to individual 
E6/E7 sequences belonging to the probes pool for HPV16/35/31 types (Fig. 25). 
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Fig. 25 Prevalence of HPV types detected with ProDect® CHIP HPV TYPING PLUS - single infection 
 
As already reported multiple infections are more frequent if you run screening by 
ProDect® CHIP HPV TYPING PLUS (Figure 23B) and a certain amount of samples has 
actually often 3, 4 and more genotypes involved in the infection. 
 
Example from this point of view, the subpopulation of women who are HIV positive 
(11/171) that analyzed by ProDect® CHIP HPV TYPING  were 3 negative and 8 were 
positive for HPV, and between the 8 positive, 5 were infected by a single HPV type. 
Analyzed by ProDect® CHIP HPV TYPING PLUS in development only 1/8 showed a single 
infection (Figure 26 A,B) supported by a HPV35 while all the others showed multiple 
infections where in 4 out of 8 cases was involved HPV16 genotype. 
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A  
ProDect CHIP HPV TYPING 
 
B  
ProDect CHIP HPV TYPING PLUS 
 
Fig. 26A-B Single and multiple infections detected with ProDect® CHIP HPV TYPING (A) and with ProDect® 
CHIP HPV TYPING PLUS (B) in the sub-sample of HIV-infected women 
 
 
Stratifying sampled HPV positive population with respect to the PAP test, it is observed 
a classic pyramid distribution (Fig. 27), with a very small proportion of high-grade lesions 
compared with a higher incidence of infection. It reveals a wide variety of genotypes in 
women who have undergone a normal PAP TEST (Fig. 28), which, however, is substantially 
reduced with the progression of the cytologic severity as expected on the basis of 
epidemiological data reported in the literature. However, at least in this population, when 
searched, are highlighted in the ASC-H, HSIL, AGC and SSC condition, uncommon 
genotypes or considered low oncogenic risk (HPV 52,59,81,82,66,67,6,30/40), in co-infection 
with another one or with the most frequent HR HPV types (HPV16, 18, 45), Fig. 29. 
64 
  
Fig. 27 HPV infected samples with respects to cytological PAP Test 
 
 
 
Fig. 28 HPV types present in the infected samples with respects to cytological PAP Tests 
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Fig. 29 Prevalence of HPV types in cytological high-grade dysplasia  
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5. Discussion 
Up to the last decade, cervical cancer had been second most common cancer in women 
for incidence and mortality after breast cancer. At the base of the neoplastic process the 
establishment of a persistent infection by certain genotypes of the human Papillomavirus 
(HPV). Organized screening programs for cytological and molecular testing, at least in most 
developed countries, have, however, contributed significantly to the reduction of the cases in 
terms of both incidence and mortality. Currently it is the 4th leading cause of death from 
cancer among women worldwide. 
 
To complicate the tasks of screening and prevention, there are some significant issues: 
 
From a cytological point of view, the presence of so-called cadres "ASC-US" addressed 
subsequently in colposcopies are often already CIN2 or more severe. In Italy the National 
Observatory Screening records last report in 2014 that, based on the data reported by the 
regional centers for screening, the national average, with probability of having a CIN2 
histological lesion or more severe among women who have undergone a ASCUS cytology is 
15.8%, the national average, with an appreciable variability as a result of geographic areas 
(16.8% in the North, 21.2% in the Centre and 10% in the South and the Islands)[135] 
 
From a molecular point of view, there is an incomplete knowledge of the HPV-host 
mechanisms interaction at the base of the infection, its course and its possible persistence. In 
fact there is great heterogeneity of circulating HPV genotypes, of which more than thirty are 
high tropism anogenital, classified on the epidemiological database for  high-medium or low 
oncogenic risk types, capable of multiplying only in multi-layered epithelia (therefore, 
difficult to grow in vitro) and where establish infections characterized by productive and 
latent stages, and where the genomes can be in the episomal and/or integrated form. 
 
The development and spread of prophylactic vaccines against HPV16, HPV18, 
recognized at the moment as etiological agents, for about 70% of cervical cancers, hopefully 
in the near future could lead to a further substantial reduction of CIN2 and CIN3 cases due to 
these genotypes, but proposes a substantial problem today, to make a careful assessment of 
the virological condition of the woman at the time of vaccination, and to start, in the most 
general sense, to closely monitor circulating types. In fact, with the vaccination expansion  
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other genotypes at high oncogenic risk, which current vaccines have little or no effect, might 
tend to spread. To confirm what has been said, surveillance needs to be increasingly precise 
and especially the improved of techniques in molecular biology are leading to a continuous 
re-classification of the medium and low risk types to higher levels of oncogenic risk, 
especially if detected in particular population categories. In fact, the persistent infection of 
some HPV is necessary, but clearly not sufficient for tumor development, and other genetic 
factors and host immune systems, as well as environmental, contribute to the disease onset 
and progression, or vice versa, contribute to its spontaneous resolution both in terms of 
infection and precancerous lesion. 
 
Important changes are therefore in progress in the cervical cancer screening approach, 
and many other HPV related cancers, so that different nations and also Italian regions[136] 
have already defined the HPV test as the primary test and the PAP test as a triage, to be 
applied only to HPV positive women, in order to distinguish those which have obvious 
cytologic atypia and thus a greater risk of disease progression, from those that can, with time, 
resolve the infection spontaneously in the absence of atypia or moderate dysplasia[137]. This 
non secondary aspect will allow a greater period of time for monitoring woman, much more 
extended in the presence of a negative HPV test. In this regard WHO[138] defining new 
criteria for organized screening that: 
 
• the interval between controls (frequency of screening) should not be less than five 
years, when using HPV testing as a primary test, 
 
• women less than 30 years old are not screened if not HIV infected or from geographic 
areas with a high HIV prevalence  
 
• at national level programs, as a minimum, screening should involve women aged 
between 30-49 years 
 
An in vitro diagnostic device that is proposed as a molecular test to be used in the 
cervical cancer screening, so for next 15-20 years, must obviously taking into account all 
these aspects. It must support clinical, and health organization upstream in the development of 
algorithms that address the specific problems of various subpopulations in a risk women 
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sample, or potentially all women aged >15 years (about 3.45 billion of women in the world) 
that actually include various subpopulations. In light of the foregoing, the HPV test should 
ideally be able to: 
 
1. diagnose the state  or at least the infection of the woman or even if the virus was 
integrated or at least in a latent form, 
 
2. discriminate individual from multiple infections 
 
3. characterize largest number of genotypes with anogenital tropism in order to: 
a. diagnose infections with other HR HPV not covered by the vaccine in women 
vaccinated a while before, 
 
b. monitor course of women already infected with HPV to which current vaccines 
are not therapeutic, 
 
c. assesses the real absence of HPV sequences in women undergoing on treatment. 
In fact, it is still significant relapse rate[139-143]: around 20% at 5 years in the 
absence of lymph node localization to the first treatment, and up to 70% within 
10 years in case of lymph node metastases, 
 
d. also characterize HPV rare or defined as low-risk types that in certain population 
such as immunosuppressed women for several factors (HIV+, therapies, genetic 
conditions etc. etc.) could alone or in co-infection with other types and/or 
pathogens enhance speeding and severity of neoplastic disease progression. 
 
In this context the realization of this research project was born and founded, aimed to 
design a diagnostic kit that would by the first to meet the substantial prerequisites for a 
molecular test to be used in primary screening programs with frequency no less than five 
years, or to discriminate, with reasonable certainty, women non HPV infected from those 
infected, being able to recall not infected after five years after a subsequent control, and to 
start with the infected by cytological triage to characterize and/or monitor any lesions. 
 
The developed prototype, ProDect® CHIP HPV TYPING PLUS provides amplification 
starting from an extract nucleic acid of three genetic substantial targets for the proper 
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management of a woman included in a screening organized program: the human β-globin 
gene, as a marker of the DNA appropriate amount and then of the sample collected cellularity, 
the L1 region for the typing of more than 30 HPV types with high anogenital tropism and the 
E6/E7 region for targeted monitoring and further genotypes with high and medium oncogenic 
risk that could escape to a possible detection on the L1 region for low viral load, reduced 
number of copies or loss of viral genomic sequences as a result of virus integration into the 
cellular genome. 
 
A preliminary assessment of the diagnostic test performance, once individual 
components concentrations were calibrated and  8 pre series batches  prepared,  the 
assessment was performed on the clones, cell lines and clinical samples. The tests were 
conducted in parallel using two kits already on the market, ProDect® CHIP HPV TYPING 
and Hybrid Capture® 2 (HC2) HPV Test, in order to evaluate the actual contribution of this 
new test to a more accurate HPV infection diagnosis. For the prototype preliminary validation 
a female population at particular risk of disease from a geographic area with high prevalence 
of HPV but also HIV was chosen, Benin, with reduced economic resources devoted to the 
screening programs organization and therefore in need of accurate and decisive test with high 
negative predictive values.  In fact, in these socio-health, given the reduced instrumental and 
logistics means, it is of utmost importance to identify with reasonable certainty HPV negative 
women, compared to those HPV positive, in order to rationalize spending in full health 
protection for women. 
 
This study found that in terms of sensitivity for HPV common types, the ProDect® 
CHIP HPV TYPING PLUS shows comparable performance to the reference tests used: 
ProDect®CHIP HPV TYPING and Hybrid Capture® 2 (HC2) HPV Test . Compared to the 
Hybrid Capture® 2 (HC2) HPV Test results to be 10-100 times more sensible in detecting bcs 
Biotech cloned containing L1-E6/E7 regions in the same insert. There is no evidence of 
nonspecific signs to the highest tested cloned concentrations (106-107 copies/µl) in any of the 
three tests.  However, calculating  the diagnostic capabilities compared to the virus presence 
in the population can be seen, as a certain sample proportions, the infection has been 
underestimated. In fact, subject to the reference tests used from 10% to 20% of the samples 
resulting as negative (false negatives) and many infections are incurred by individual 
genotypes, indeed several are co-infections genotypes. So, even though all are excellent 
screening tests (in practice are considered good screening test those who have >80% 
70 
sensitivity and specificity) the new prototype in this preliminary study demonstrates a higher 
VPN (ProDect® CHIP HPV TYPING PLUS VPN = 98.8%). It was exhibited a very high VPP 
(100%), with a strong HPV prevalence the analyzed population, supported in part by 
genotypes undetectable with other tests utilized(which in fact are therefore less sensitive than 
expected, not covering these viral types). This aspect is relevant from an epidemiological 
point of view: in fact in some contexts such as African or in particular portions of the 
population at high risk/prevalence of infection, using tests that do not cover a large types, 
underestimated numbers in the total infections and the role of some oncogenic genotypes that 
in specific socio-environmental-health have low oncogenic potential, but in different contexts, 
and in co-infections with other pathogens or specific HPV types, may be contrarily highly 
oncogenic. The data, although preliminary, opens up further general discussions of the 
desirability in adopting as the primary cervical cancer screening, being the only test revealing, 
often without genotyping, high oncogenic risk HPV. It appears intuitive that even if such an 
approach involves a certain reduction in costs related to screening, moreover to prove, a test 
that also genotype all anogenital genotypes and maybe not in manual procedure may also be 
provided at lower cost, with time and natural epidemiological changes to all infections caused 
by viral genotypes undergo, it may not be sufficient, with savings in the short term but an 
increase in health care costs in the medium to long term. In the near future prophylaxis, in 
industrialized countries, and with well-organized health organizations, will further reduce the 
disease incidence and the prevalence of the major HR HPV, in primis HPV16 and HPV18, 
while the use of only HR screening tests in populations or segments of the population with 
high prevalence of HPV infection in the presence of concomitant infections (e.g. HIV, HCV, 
Chlamydia etc.), immune depression or other pathologies can lead to a significant 
underestimation of types circulating and their oncogenic potential, given that many HPV 
medium risk types or types being not well classified, as little or no research in a certain 
contexts may have greater significance instead. If what emerged, was shown that the reduced 
sample size reflected that of wider studies, it would be advised not to limit the possibility of 
molecular testing as an organized screening program for HR genotypes only, but vice versa, 
trying to cover the prevalence of the infection, types actually circulating in the population 
sample, in order to establish effective vaccination plans especially in developing or developed 
countries, but not yet well organized for capillary primary screening, as some Eastern 
European State members, where unfortunately incidence and mortality due to cervical cancer 
data are still very high, with a high infection and genotypes prevalence of no clear 
classification. The study also highlights how sample conformity is a concept for a substantial 
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molecular screening test aimed at cervical cancer diagnosis. In fact, from the anatomo-
pathological point of view characteristics have been established to define a suitably PAP test 
in terms of representativeness of the different layers of the endocervical mucosa and epithelial 
transition, it should not be sufficient for a molecular test to establish the conformity based on 
the amplificability of a DNA control, both viral or human sequence. It would substantial to 
determine and identify a cellularity cutoff and consequently nucleic acid obtained from the 
biological sample taken with reasonable certainty, and with any molecular method used, and 
would guarantee the clinician a probable negativity of the sample for HPV sequences. Indeed, 
the probability of highlighting the virus in not-replicative phase or integrated and/or with 
incomplete genomes has as a prerequisite that a reasonable amount of cells (> 105) extracted 
with a fair and qualitatively good amount of total nucleic acid, in order to reveal even a few 
viral copies (10-100 copies), without ever dropping below sensitivity threshold in the method 
used (theoretical 10 copies for PCR), in order to avoid an incorrect negativity sample 
diagnosis for HPV sequences, obviously less represented with respects to the human gene or 
internal control considered by most diagnostic tests on the market. Even this is also not a 
negligible aspect if you look at the cases of women who have a negative molecular test result 
(not on the basis of cellularity but often by the absence of HPV sequences) and a positive 
PAP test, show obvious lesions by colposcopy or following up after a first molecular negative 
test have recurrent disease often incurred by the  same HR genotypes, or from different types 
usually underestimated in primary screening considered at low-medium risk and are often in 
co-infection with HR types. A molecular test characterized by an accurate monitoring of levy 
adequacy would probably be able to further reduce the number of false negatives due to 
withdrawals of inadequate diagnostic sampling and the type of virus being searched for. 
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6. Conclusion 
The multi-target approach is the new frontier of molecular diagnostics since the 
acquisition of more and more in-depth knowledge about the etiology of cervical cancer 
compels manufacturers of medical devices to focus on the prevention, diagnosis and treatment 
of this disease and keep up to date in state of the art and continuously innovate their 
platforms. 
In this context, the applied research conducted in these three years has led to the 
design, development and production of a new test prototype multi-target, able to diagnose 
HPV infection in cervical-vaginal spatula samples having two genomic target sequences of 
the virus: the L1 region essential for the genotyping of the virus and the E6 / E7 region to 
detect the presence of higher risk oncogenic HPV, even in cases with the loss of more or less 
extensive portions of the genome as in the case of the integrated viral forms. 
 
The prototype attributes the negativity or positivity of each sample based on a quantity/quality 
of DNA extracted from cells harvested at the time of sample collection (at least 105 cells/ml) 
so that we can define compliance for sampling and guarantees a cell representation that will 
allow us statistically, using gene amplification techniques, amplify of a few copies of the 
HPV target sequences, if the infection is latent or abortive, to whether or not the virus has 
integrated into the cellular genome. 
 
The first tests on the complete diagnostic platform (extraction, amplification and 
detection) show that the system has a specificity and diagnostic sensitivity similar to those of 
the reference test, the Hybrid Capture® 2 (HC2) HPV Test, currently the most utilized in 
screening programs worldwide, presents, in addition, the advantage of a procurement 
compliance control as a function of cellular sampling and not the sole function of testing for 
the presence/absence of the virus. It also allows with respect to the reference test an 
immediate classification of the viral genotype over two sequences of genotype in question, at 
least for the HPV-HR (reg.L1 and reg.E6/E7), moreover being able to characterize up to 31 
HPV types, against 13 HPV-HR of the reference test in a single session per sample.  
 
The ProDect® CHIP HPV TYPING PLUS is a natural and necessary evolution of ProDect® 
CHIP HPV TYPING, diagnostic kit already CE marked, additionally presents, the ability to 
characterize on a chip a higher density of probes, more anogenital genotypes over 19 already 
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typable with the kits currently on the market, and to characterize the region of E6/E7 of HPV-
HR defining the homology with three pool of probes which react to the same number of 
groups of high-risk HPV (group 1: E6 / E7HPV16,31,35 , 2nd group E6 / E7HPV18,45, 3rd 
group E6 / E7HPV33 / 52/58/56/66/67/82/59). 
 
Preliminary data show that the inclusion of new probes on the chip did not have an 
increase in cross reaction nor the difficulties of acquisition and analysis by the reading system 
chip, whose software was simply implemented with the new pattern of interpretation results. 
 
In conclusion, the main objective has been reached, that is, to produce a test with high 
specificity (comparable to that of the two reference tests) but at the same time with a higher 
Negative Predictive Value. The validation of 171 cervical spatulas samples made it possible 
to recover a significant amount of negative data samples with regards to the reference tests 
employed (22% with respects to Hybrid Capture®2 (HC2) HPV Test and 10% compared to 
ProDect® CHIP TYPING HPV), which conversely analyzed with the new prototype resulted 
in positive for the sequences for medium and low risk types of HPV. 
 
These encouraging results, as well as the grant for the patent EP1818416 B1 "Methods 
and Kits for the detection of HPV" dated 26.12.2012 (EPO Bulletin 2012/52) and its 
nationalization of the same in different countries as of 2013, laid the foundations for the 
opening of independent clinical trials and multi-centers, as required by rule concerning the 
risk assessment and management for in Vitro Diagnostic Devices, before the CE markings on 
the kit and entering in to the commercial market, which are the subject of a proposal from the 
bcs Biotech Srl currently under evaluation by the EU Commission, as part of the invitation 
HORIZON2020, SMEInst-2014/15: Clinical research for the validation of biomarkers and / or 
diagnostic medical devices. 
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8. Apendix – Raw data of samples tested 
SUBJECT AGE PAP TEST ProDect
®CHIP HPV 
TYPING 
ProDect®CHIP HPV 
TYPING PLUS HC2 SEQ 
FINAL 
DIAGNOSIS 
015 BIS 21 ASCUS HPV 18, E6/E7 HPV18,81 HR HPV18,81 HPV18,81 
019 BIS 25 Negative HPV 16 HPV81, 11, E6/E716/35/31 HR+LR HPV16 HPV16,81,11 
001SL 38 Negative HPV31 E6/E7 HPVE6/E716/35/31 HR+LR HPV31 HPV31 
004SL 18 Negative Negative Negative Negative neg Negative 
008SL 44 Negative Negative Negative Negative neg Negative 
017SL 28 ASCUS HPV16, 45 HPV 31,16 HR+LR HPV16 HPV16,45,31 
042SL 27 Negative Negative Negative Negative neg Negative 
048SL 29 H-SIL HPVE6/E7 HPVE6/E716/35/31 HR HPV16 HPVE6/E716/35/31 
049SL 44 Negative Negative Negative Negative neg Negative 
065SL 50 ASC-H HPV18,45,E6/E7 HPV18,40 HR+LR HPV18 HPV18,45,40 
067SL 36 ASCUS HPV18,35 HPV40,E6/E7 HR HPV18,35 HPV18,35,40 
113SL  40 ASCUS HPV73 HPV81,70 HR+LR HPV73 HPV 73, 81,70 
008 PK 42 Negative HPV59 HPV81,35,E6/E7 HR HPV59,35 HPV59,35,81 
019PK 29 Negative HPV35,E6/E7 HPV35,40,E6/E716/35/31 HR HPV35 HPV35,40 
021PK 35 ASCUS HPV59 HPV16,40,E6/E7 HR HPV16,59 HPV59,40,16 
030PK 28 Negative HPV59 HPV81,16, E6/E7 HR HPV16,59 HPV81,16,59 
033PK 38 AGC HPV59 HPV16,40,67,70,81,E6/E7 HR+LR HPV16,59,67 HPV59,16,40,67,70,81 
041PK 50 Negative HPV 6/11,E6/E7 HPV 35, 58, E6/E7 HR+LR HPV35 HPV35, 58, 6/11 
14HO 27 Negative HPV35,51,58,59,E6/E7 HPV35, E6/E716/31/35 HR+LR HPV35 HPV35,51,58,59 
15HO 46 Negative HPV16,35,59,45,E6/E7 HPV35,16,59,E6/E7 HR HPV16,35 HPV16,35,59,45 
18HO 34 Negative HPV35,59,18 HPVE6/E7 Negative HPV35 HPV35,59,18 
19HO 29 Negative HPV35,58,42,59  HPVE6/E716/31/35 HR HPV35 HPV35,58,42,59 
20HO 25 Negative HPV58  HPVE6/E733/58 HR HPV58 HPV58 
21HO 58 Negative HPV73,59 HPV 40 HR+LR HPV73 HPV73,59,40 
23HO 35 ASCUS HPVE6/E7 HPVE6/E716/35/31 Negative HPV31 HPVE6/E716/35/31 
24HO 52 Negative Negative HPV81, E6/E733/58 Negative HPV81 HPV81,E6/E733/58 
25HO 49 Negative HPVE6/E7  HPVE6/E716/35/31, 33/58/52 Negative HPV16 6/E716/35/31,E6/E733/58 
1LK 26 ASCUS HPV16 E6/E7 HPV16, 33, 40, E6/E7 HR HPV16,33 HPV16, 33, 40 
2LK 38 Negative Negative Negative Negative neg Negative 
5LK 28 ASC-H Negative Negative Negative neg Negative 
7LK 57 Negative HPV42 HPV42 HR+LR HPV42 HPV42 
11LK 31 Negative HPV42, 52 HPV42,52,70 LR HPV42,52 HPV42,52,70 
27LK 20 ASCUS HPV58 HPV58,81,E6/E7 33/58/52 HR HPV58 HPV58,81 
39LK 40 Negative HPV33,16,E6/E7 HPV16,33,67,81,E6/E7 HR HPV16,33 HPV16,33,67,81 
40LK 33  ASCUS HPV59 HPV 59,16,E6/E7  HR HPV59,16 HPV 59,16 
41LK 44 Negative HPVE6/E7 HPVE6/E716/35/31 Negative HPV35 HPVE6/E716/35/31 
42LK 32 AGC HPV18,E6/E7 HPV18,31, E6/E7 HR+LR HPV18 HPV18,31 
43LK 54 Negative HPV58,59,18 HPVE6/E733/58 HR HPV58 HPV58,59,18 
44LK 33 AGC HPV16,E6/E7 HPV16,81,E6/E716/35/31  HR HPV16 HPV16,81 
45LK 33 ASC-H Negative Negative Negative neg Negative 
47LK 37 H-SIL HPV52, E6/E7 HPV40,81,16,E6/E7  HR HPV52,16 HPV52,16,40,81 
49LK 35 Negative Negative Negative Negative neg Negative 
50LK 30 ASCUS HPV59 HPV59,35,40,E6/E7 HR HPV59 HPV59,35,40 
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51LK 47 ASC-H HPV59 HPV81,E6/E7 33/58/52 HR HPV59 HPV59,81 
52LK 43 ASCUS Negative Negative Negative neg Negative 
001TG 47 ASCUS Negative Negative Negative neg Negative 
002TG 50 Negative HPV16,E6/E7 HPVE6/E716/35/31 HR HPV16 HPV16 
003TG 26 Negative HPV35, 42 HPV35, 42 HR+LR HPV35,42 HPV35, 42 
004TG 27 H-SIL SCC Negative HPV66,82,E6/E7 Negative HPV66,82 HPV66,82 
005TG 24 Negative HPVE6/E7 HPV31, E6/E733/58 Negative HPV31 HPV31, E6/E733/58 
016TG 38 ASCUS Negative Negative Negative neg Negative 
019TG 33 ASCUS Negative Negative Negative neg Negative 
020TG 35 ASCUS HPV16, 6/11 HPV11,81,40,16,E6/E7 LR HPV16,11 HPV16,11,81,40 
031TG 39 Negative HPV 16,35,E6/E7 HPV16,35,E6/E7 HR HPV16,35 HPV16,35 
034TG 31 Negative Negative Negative Negative neg Negative 
036TG 36 Negative Negative Negative Negative neg Negative 
041TG 39 Negative Negative HPV40 Negative HPV40 HPV40 
012AB 50 H-SIL HPV16,45, E6/E7 HPV16, 45,E6/E716/35/31 HR HPV16,45 HPV16,45 
049AB 44 H-SIL HPV58 HPV81,E6/E7 33/58 HR HPV58,81 HPV58,81 
03PN 55 Negative Negative Negative Negative neg Negative 
05PN 63 Negative Negative Negative Negative neg Negative 
06PN 59 Negative Negative HPV81 Negative HPV81 HPV81 
07PN 28 Negative HPV 16 HPVE6/E716/35/31 Negative HPV16 HPV16 
08PN 45 Negative Negative Negative Negative neg Negative 
10PN 23 Negative HPVE6/E7 HPVE6/E716/35/31, E6/E733/58 Negative HPV16 6/E716/35/31,E6/E733/58 
11PN 54 Negative Negative Negative Negative neg Negative 
12PN 39 Negative HPV 16 HPVE6/E716/35/31 HR HPV16 HPV16 
13PN 15 ASCUS HPV 56 Negative Negative HPV56 HPV56 
14PN 31 ASCUS HPV 16, E6/E7 HPVE6/E716/35/31 HR HPV16 HPV16 
15PN 44 Negative Negative Negative Negative neg Negative 
17PN 35 Negative Negative Negative Negative neg Negative 
18PN 39 ASC-H HPV 52 HPV35,E6/E716/35/31, 33/58/52 HR+LR HPV52,35 HPV52,35 
20PN 58 Negative Negative Negative Negative neg Negative 
21PN 20 Negative Negative Negative Negative neg Negative 
22PN 40 Negative Negative Negative Negative neg Negative 
24PN 25 Negative Negative Negative Negative neg Negative 
26PN 37 ASCUS HPV6/11 HPV6 LR HPV6 HPV6 
27PN 49 Negative HPVE6/E7 HPVE6/E733/58 Negative HPV52 HPVE6/E733/58 
28PN 55 Negative Negative Negative Negative neg Negative 
29PN 39 Negative Negative HPV67 Negative HPV67 HPV67 
31PN 46 Negative Negative Negative Negative neg Negative 
33PN 22 ASCUS HPV56 HPV56,40, E6/E7 Negative HPV56 HPV56,40 
37PN 54 Negative Negative Negative Negative neg Negative 
39PN 34 Negative Negative Negative Negative neg Negative 
40PN 30 ASCUS Negative Negative Negative neg Negative 
43PN 49 Negative Negative Negative Negative neg Negative 
44PN 50 AGC HPVE6/E7 HPVE6/E716/35/31 HR HPV35 HPVE6/E7 16/35/31 
50PN 26 Negative Negative Negative Negative neg Negative 
01 DJ 39 Negative Negative Negative Negative neg Negative 
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02 DJ 20 Negative Negative Negative Negative neg Negative 
03 DJ 22 Negative Negative Negative Negative neg Negative 
04 DJ 24 Negative Negative Negative Negative neg Negative 
05 DJ 21 Negative Negative Negative Negative neg Negative 
06 DJ 27 Negative Negative Negative Negative neg Negative 
07 DJ 20 Negative Negative HPV67 Negative HPV67 HPV67 
08 DJ 42 Negative Negative Negative Negative neg Negative 
09 DJ 28 Negative Negative Negative Negative neg Negative 
10DJ 35 Negative Negative Negative Negative neg Negative 
13 DJ 27 Negative HPV56 HPVE6/E733/56/58 HR HPV56 HPV56 
15 DJ 25 ASCUS Negative HPV40 Negative HPV40 HPV40 
4 AT 28 LSIL HPV16,E6//E7 HPV16,58,E6/E716/35/31,33/58 HR HPV16 HPV16,58 
7 AT 21 Negative HPVE6/E7 HPVE6/E716/35/31 HR HPV35 HPVE6/E716/35/31 
33 AT 41 ASCUS HPV 42, 33 HPVE6/E733/58 HR+LR HPV33,42 HPV42,E6/E733/58 
35 AT 31 ASCUS HPV 58, 45 HPVE6/E733/58 HR HPV58 HPV58,45 
27 HO 36 Negative Negative Negative Negative neg Negative 
29 HO 47 Negative Negative Negative Negative neg Negative 
30 HO 43 Negative Negative Negative Negative neg Negative 
31 HO 30 Negative Negative Negative Negative neg Negative 
32 HO 47 AGC Negative Negative Negative neg Negative 
33 HO 45 Negative Negative Negative Negative neg Negative 
34 HO 34 ASCUS Negative Negative Negative neg Negative 
38 HO 62 Negative Negative Negative Negative neg Negative 
39 HO 33 Negative Negative Negative Negative neg Negative 
40 HO 54 Negative Negative Negative Negative neg Negative 
41 HO 59 Negative Negative Negative Negative neg Negative 
46 HO 51 Negative Negative Negative Negative neg Negative 
48 HO 24 LSIL HPV 6/11 HPV6 LR HPV6 HPV6/11 
50 HO 33 Negative Negative Negative Negative neg Negative 
53 PN 58 Negative Negative Negative Negative neg Negative 
56 PN 62 Negative Negative Negative Negative neg Negative 
57 PN 57 Negative Negative Negative Negative neg Negative 
58 PN 55 Negative Negative Negative Negative neg Negative 
62 PN 54 Negative Negative Negative Negative neg Negative 
63 PN 55 Negative Negative Negative Negative neg Negative 
64 PN 53 Negative Negative Negative Negative neg Negative 
69 PN 35 Negative Negative Negative Negative neg Negative 
70 PN 53 Negative Negative Negative Negative neg Negative 
71 PN 52 Negative Negative Negative Negative neg Negative 
72 PN 39 Negative Negative Negative Negative neg Negative 
75 PN 54 Negative Negative Negative Negative neg Negative 
76 PN 38 Negative Negative Negative Negative neg Negative 
78 PN 31 ASCUS Negative Negative Negative neg Negative 
80 PN 36 Negative Negative Negative Negative neg Negative 
81 PN 44 Negative Negative Negative Negative neg Negative 
84 PN 31 Negative Negative Negative Negative neg Negative 
90 
85 PN 57 Negative Negative Negative Negative neg Negative 
86 PN 42 Negative Negative Negative Negative neg Negative 
87 PN 36 ASCUS Negative Negative Negative neg Negative 
88 PN 38 Negative Negative Negative Negative neg Negative 
89 PN 55 Negative Negative HPV81 Negative HPV81 HPV81 
90 PN 59 ASCUS Negative Negative Negative neg Negative 
93 PN 47 ASCUS HPV 33,45,43 HPVE6/E733/58 HR HPV45,33 HPV 33,45,43 
96 PN 43 Negative Negative Negative Negative neg Negative 
97 PN 40 Negative Negative Negative Negative neg Negative 
2012.137SL 52 ASCUS HPV18,E6/E7 HPV18,30/40,E6/E718/45, 16/35 HR HPV18 HPV18, 30/40 
2012.139SL 50 Negative Negative Negative Negative neg Negative 
2012.140SL 46 Negative HPV18,E6/E7 HPV18,E6/E718/45 HR HPV18 HPV18 
2012.146SL 34 Negative Negative Negative Negative neg Negative 
2012.151SL 26 Negative Negative Negative Negative neg Negative 
2012.152SL 25 Negative Negative Negative Negative neg Negative 
2012.155SL 26 ASCUS HPV6/11 HPV11 LR HPV11 HPV11 
2012.156SL 28 Negative Negative Negative Negative neg Negative 
2012.158SL 40 ASCUS HPV59, E6/E7 HPV59  HR HPV59 HPV59 
2012.161SL 31 Negative HPV58, E6/E7 HPV58, E6/E733/52/58/56/66/59 HR HPV58 HPV58 
2012.162SL 41 AGC HPV52 HPVE6/E733/52/58/56/66/59 HR HPV52 HPV52 
2012.163SL 43 ASCUS HPV51 HPV51 HR+LR HPV51 HPV51 
2012.164SL 46 ASCUS HPV39, HPV51, E6/E7 HPVE6/E716/35/31 HR HPV39,51 HPV39, HPV51 
2012.165SL 38 Negative Negative Negative Negative neg Negative 
2012.166SL 57 Negative HPV52 HPVE6/E733/52/58/56/66/59 HR HPV52 HPV52 
2012.026BIS 28 ASC-H HPV16,E6/E7 HPV16,81,E6/E716/35/31  HR HPV16,81 HPV16,81 
2012.032BIS 32 Negative Negative Negative Negative neg Negative 
2012.071BIS 62 Negative Negative Negative Negative neg Negative 
2012.001LK 42 H-SIL HPV6/11 HPV6 LR HPV6 HPV6 
2012.002LK 40 Negative Negative Negative Negative neg Negative 
2012.003LK 40 H-SIL Negative Negative Negative neg Negative 
2012.004LK 43 Negative Negative Negative Negative neg Negative 
2012.005LK 47 Negative Negative Negative Negative neg Negative 
2012.006LK 36 Negative HPV31, E6/E7 HPV31,45,70/72, E6/E716/35/31 HR HPV31,45 HPV31,HPV45,HPV70/72 
2012.008AB 30 Negative HPV18,E6/E7 HPV18, E6/E718/45 HR HPV18 HPV18 
2012.009AB 48 Negative HPVE6/E7 HPVE6/E716/35/31 HR HPV16 HPVE6/E716/35/31 
2012.010AB 45 Negative HPV18,E6/E7 HPV18, E6/E718/45, 16/35/31 HR+LR HPV18 HPV18, E6/E716/35/31 
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CHAPTER 2 - THE STUDY OF GENOMES IN SARDINIAN INDIVIDUALS AFFECTED 
AND NON-AFFECTED FROM MULTIFACTORIAL DISEASES 
1. Background 
This work was aimed at searching for genetic factors responsible for common 
multifactorial diseases. The strategy used was an indirect association using a case-control 
method. An essential requisite for this type of study is that the controls and patients pertain to 
the same population. Moreover, this population must be homogeneous and without ethnic 
stratifications to ensure that associations among causal disease variants and the genetic 
markers in the vicinity are due to linkage disequilibrium and not to other factors. 
 
The Sardinian population is one of the most homogeneous populations in Europe with a 
millenary history of scarce and lowly significant external gene influx. The island distribution 
of the population has long been influenced by historical (invasions and wars) and climatic-
environmental factors (malaria) but above all by the particular orographical structure of the 
territory. This gave rise to numerous and more or less vast and populated genetic isolates that 
were necessarily faced with phenomena of casual genetic drift and selection (ß°39 
thalassemia, G-6-PD deficiency), all of which led to a certain degree of heterogeneity of the 
population in different geographical areas. 
 
Based on studies of numerous genetic polymorphisms, including microsatellites and the 
HLA loci, the genetist[1-8] divided the Island of Sardinia into 32 geographical areas 
characterized by high internal genetic homogeneity and microheterogeneity among areas 
(FST= 0,0068 ± 0,0015). Only for the mutations ßth and G6PD¯(adaptive), heterogeneity 
(FST= 0,0430) clearly existed between the populations of the highlands (not exposed to 
malaria) and those of the lowlands (exposed to malaria). 
 
1.1. Choice of the geographical areas 
In order to reduce to a minimum the possibility of bias due to dyshomogeneity or 
stratification within the population groups to be selected for the study of association, we made 
a major effort to establish if and which populations residing in the previously individuated 32 
geographical areas were substantially mendelian breeding units (MBU). In each geographical 
area we chose 2-4 villages representative of the geographical population and number of 
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inhabitants, for a total of 94 villages. In each village, we analyzed all the matrimonies 
celebrated over the past 150 years, distinguishing between the place of origin of the married 
couples (from the same village, other villages of the same area, villages of other areas). We 
then evaluated the mean endogamy index for each village and each area. We also evaluated 
the relative migration rates. 
 
For the study, we selected villages or geographical areas with a mean endogamy index 
of ≥0,50 and a mean immigration rate of ≤0,085, which we considered as MBU. The number 
of inhabitants of the MBUs selected for the study ranged from ≥15.000 to ≤ 65.000. 
 
1.2. Selection of the Controls 
A preliminary choice of the controls in each MBU was made through the local 
community anagraphical registrars with a primary selection of residents aged ≥ 35 year 
pertaining to different family nuclei and born to parents of the same MBU. After obtaining 
informed consent for participation to the study, we constructed family trees up to the 4° – 5°  
generation, including, for each participant, name and surname, date and place of birth, 
eventual cause of death and the presence or absence of common multifactorial diseases. All of 
the family trees of a given MBU lacking the presence of multifactorial diseases underwent 
analyses with a special program specifically designed to identify and exclude: 1) trees with 
ancestors originating from different MBUs and 2) trees with one or more members related to 
members of other trees. In this way, the individuals selected as controls in each MBU were: 1) 
descendents of ancestors all originating from the same MBU up to the 4° – 5° generation, 2) 
not related among each other, and 3) presumably not affected by common multifactorial 
diseases. 
 
1.3. Selection of affected probands 
A preliminary choice of probands affected by common multifactorial diseases in the 
selected MBUs was made with the assistance of general practitioners and specialist services 
such as the Antidiabetes Centers and Services of Rheumatology, Dermatology, Neurology 
and Endocrinology etc. After obtaining informed consent for participation to the study, we 
completed the family trees for each proband up to the 4°-5° generation and then proceeded 
with the final selection of the affected probands in each MBU taking care, as for the controls, 
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that the selected probands were not related with other probands and that their ancestors all 
originated from the same MBU up to the 4°-5° generation. 
The number of controls and affected subjects is given in Tab. 1 below.  
 
Biobank DNAs were collected as part of various projects, of which the last two funded 
by Sardegna Ricerche via BCS BIOTECH between 2006 and 2009 years entitled respectively, 
“Development of new bioinformatics methods for the detection of environmental and genetic 
causes of multifactorial diseases in Ogliastra” and  “Detection of the genes responsible for 
autoimmune Hypothyroidism and for Hashimoto Disease in Ogliastra”, Prof.L.Contu was the 
Scientific Head for both projects. 
 
 
 Samples** 
*DNA from → 
 
528            Controls 
201            Type 1 Diabetes 
93              Hashimoto Disease 
96              Multinodular Goiter 
24              Schizophrenia 
143            Longevity 
81              Myopia 
573            Other Diseases 
 
Tab. 1. Samples of controls and probands affected by multifactorial diseases that are currently stored 
in BCS BIOTECH Biobank. *Many patients have 2 or much more diseases. 
** The samples were collected in different areas of the south, center and north of Sardinia, as well as 
in Ogliastra. 
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2. Introduction 
The first project goal, still in progress, is to create a dataset of genetic data related to  
molecular characterization of the whole genome in a population formed by a sufficiently large 
enough sample of healthy subjects, or rather have not been affected by common and 
multifactorial pathologies, and are of a known Sardinian origin to be used in association 
studies. In fact, large number of studies have demonstrated the monophyletic genetic origin 
and Sardinian peculiarities[1-9] as well as their substantial genetic homogeneity, despite 
microheterogeneity between different regions[10-11a] due to the combined effects of random 
genetic drift and migration between villages. The population is large enough and there have 
been 32 homogeneous sub regions identified with a total population of about a million 
inhabitants. The analysis of the genetic variation of the Sardinian population, considered a 
founder population, is particularly useful for association studies on complex diseases, 
especially autoimmune diseases, such as Type I diabetes and multiple sclerosis, which are 
highly represented in the island[12-14]. Therefore, having at the disposal a dataset of genetic 
healthy controls of a Sardinian population represents a fundamental tool for the study of the 
most common diseases, not only in Sardinia but in the world, and offers the possibility of an 
estimate of what could be the differences created by geographical location of subjects/patients 
groups being analyzed. 
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3. Material and methods 
3.1. Samples 
Biobank kept at the R&D laboratories of bcs Biotech, from which my research started, 
containing 528 healthy controls and 900 patient DNAs with one or more complex diseases, all 
of certain Sardinian origin, selected in different geographical Sardinia subareas and in 
particular 6 Ogliastra municipalities. For each subject the reconstruction of the genealogical 
trees up to 4°-5° generation was performed, and steps taken to exclude all the other probands 
relatives (sick and controls). All samples were managed in an anonymous way, they were 
genotyped for loci: HLA A-B-C-DQB1-DRB1, SNP-137; SNP-397; SNP-351; Haplotype -
397/-351; NALP1; HLA G; FTO (data not shown) and 234 controls were analyzed by 
Affymetrix platform. Currently being undertaken is the genotyping of patients distributed by 
disease, Tab. 1. 
 
3.2. Genotyping and quality control 
The DNA of 234 control subjects exclusively originating from Ogliastra was genotyped by 
Affymetrix Genome-Wide Human SNP 6.0 Array (Affymetrix, Inc., Santa Clara, CA, USA), 
which includes more than 906,000 SNPs and more than 946,000 probes for the Copy Number 
Variation determination[15]. 
  
The experiments were performed in the genotyping laboratory within the “Cluster” 
project, organized by Sardegna Ricerche within the scientific and technological park in Pula 
addressed at public and private research laboratories participants at the "Creating a centre of 
excellence in bio-informatic technologies applied to personalised medicine technologies" 
program funded by the Region of Sardinia following the recommended protocol as described 
in the Affymetrix manual. Briefly, total genomic DNA (500 ng) was digested with restriction 
enzymes Nsp I and Sty I, linked to the adaptors and amplified using a primer sequences that 
recognizes adaptors. Amplified DNA was fragmented, labeled and hybridized to 
oligonucleotide probes bound to the surface of the array in the GeneChip Hybridization Oven 
640 (Affymetrix, Inc., Santa Clara, CA, USA), followed by washing and staining procedures 
performed in the GeneChip Fluidics Station 450 (Affymetrix, Inc., Santa Clara, CA, USA). 
Arrays were then scanned by GeneChip Scanner 3000 7G (Affymetrix, Inc., Santa Clara, CA, 
USA). Samples intensity files were analyzed with programs included in Affymetrix Power 
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Tools (APT version 1.12.0). Quality control was performed by Constrast QC (CQC) 
algorithm, which quantifies the separation of the intensity signals for each allele in three 
different clusters in a contrast space, defined as the two-dimensional space projection of the 
allele intensity in a single informative dimension. Analyses were performed using APT-
GENO-QC executable, set with default parameters. 
 
3.3. Genotype calling and dataset filtering 
The genotypes used for the following analysis were determined by the Birdseed v2 algorithm, 
implemented in the APT-PROBESET-GENOTYPE program, using a score confidence 
threshold equal to 0.1. Analysis by Birdseed algorithm was conducted with all samples that 
had passed the quality control, as Affymetrix recommended the execution of the algorithm 
with at least 44 samples to get a more accurate genotypes determination. 
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4. Results 
The data derived from the analysis of 234 control subjects was provided for two studies in 
collaboration. 
 
4.1. Study No. 1,  
In collaboration with researchers from the following public and private Italian 
institutions: Shardna Life Sciences, University of  Cagliari – Department of Experimental 
Biology, University of Bologna – Laboratory of Molecular Anthropology, Department of 
Experimental Evolutionary Biology and that ended in to the following publication Piras I., De 
Montis A., Calò CM., Marini M., Atzori M., Corrias L., Sazzini M., Boattini A., Vona G., 
Contu L. Genome wide scan with nearly 700.000 SNPs in two sardinian subpopulations 
suggest some regions as candidate targets for positive selection. European Journal of Human 
Genetics (EJHG) 2012, 03:1-7 http://www.ncbi.nlm.nih.gov/pubmed/22535185 
 
In short, to increase genomic information on the Sardinian population, the analysis of 
both the genetic structure at the sub-regional level and the consequences of natural selection 
in two distinct Sardinia subpopulations. We analyzed 321 healthy individuals from two 
different Sardinian regions. In particular, sample datasets from Ogliastra preserved in BCS 
BIOTECH biobank have been compared to 125 Southern Sardinian sample datasets, 
conserved in the Department of Experimental Biology biobank, University of Cagliari, these 
samples were from 20 different villages distributed in three historic-neighboring geographical 
regions in central and southern Sardinia (Sulcis, Campidano and Trexenta). The information 
from nearly 700,000 informative autosomal SNPs genotyped by Affymetrix platform 6.0, 
were analyzed with several statistical approaches to determine the genomic differences at 
individual SNPs. The more differentiated regions were further analyzed using a test based on 
Extending Haplotype Homozygosity (EHH)16, which is able to detect the occurrence of 
potential "selective sweeps" in the populations genomes examined. 
 
The principal component analysis (PCA) and admixture analysis suggested a 
differentiation between the two subpopulations, as confirmed by AMOVA (Fst = 0.011; P = 
0.001). In addition, we have identified 40 genomic regions with significant differences, 
particularly in the chromosomes 1, 9, 12 and 13. These 40 regions were further analyzed with 
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the Long Range Haplotype test, which showed statistically significant values of REHH for 
rs11070188 and rs11070192 SNPs in the Ogliastra population. These markers are located on 
chromosome 15 (15q15), located less than +5 kb from the rs7181250 SNP peak, and show 
higher values of Fst. In light of SNPs analyzed, characteristics and correlation between the 
different methods used, the region characterized by these SNPs can be considered an 
important candidate that have been subjected to a population specific selective event. This 
region is defined by C15orf54 (-81 kb) and THBS1 (+244 kb) genes. In particular, the gene 
coding for the THBS1 Thrombospondin I, is a multimodular secreted protein that is linked to 
the extracellular matrix and exerts a variety of biological functions, such as platelet 
aggregation, angiogenesis, and tumorigenesis. One of these functions is also represented by 
the capacity to act as a receptor for red blood cells infected by Plasmodium falciparum, 
adhesion of which to the capillaries increases the parasite virulence. Moreover, the region 
characterized by these genes has been previously identified as a selective pressure target in 
two distinct papers[17-18]. Because of the SNPs location, in particular for the THBS1 gene 
presence, it is possible to speculate on a potential selective action by malarial infection, which 
has characterized Sardinia up to its complete eradication, which was held in the mid of last 
century[19]. Referring to the data on malaria morbidity for each village[20-21], morbidity 
average, calculated with a weighted average based on the number of samples from each 
village, would be 57.95% for Ogliastra compared to 28.56% of South Sardinia. These data 
suggest a significant presence of malaria in Ogliastra, supporting, as a working hypothesis, a 
selective event associated to malarial infection, which still needs further verification. 
 
4.1.1. Conclusion 
The published results emphasize a presence of internal differentiation within the Sardinian 
population, and support the identification of a selective sweep at a micro-geographic level that 
pertain to the Ogliastra population, such as discovery of other highly differentiated regions in 
addition to be potential candidates for selective pressure event, may represent substantial 
functional differences. Though many other studies have been performed such as genome-wide 
for the detection of regions subject to natural selection, the population utilized have always 
shown high levels of divergence, while at a micro-geographic level analysis, are quite rare. In 
this paper we report a rather plausible evidence of selective pressure right at micro-geographic 
level. Finally, it is possible to speculate that these high differences in genome specific regions 
between the two samples tested could play a role in susceptibility to complex disease[22]. 
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These results could have a predictive role for future association studies of complex diseases in 
the same subpopulations.  
 
 
4.1.2. References 
 
[1] Contu, L., Deschamps, I., Lestradet, H., Hors, J., Schmid, M., Busson, M. et al. (1982) 
HLA haplotype study of 53 juvenile insulin-dependent diabetic (I.D.D.) families. 
Tissue Antigens, 20, 123. 
[2] Contu, L., Carcassi, C. & Trucco, M. (1991) Diabetes susceptibility in Sardinia. 
Lancet, 6, 338, 65. 
[3] Piazza, A., Mayr, W.R., Contu, L., Amoroso, A., Borelli, I., Curtoni, E.S., Marcello, 
C., Moroni, A., Olivetti, E., Richiardi, P., et al. (1985) Genetic and population 
structure of four Sardinian villages. Ann Hum Genet. 49, 47. 
[4] Di Rienzo, A., Wilson, A.C. (1991) Branching pattern in the evolutionary tree for 
human mitochondrial DNA Proc Natl Acad Sci U S A. 88 (5),1597. 
[5] Contu, L., Arras, M., Carcassi, C., La Nasa, G., Mulargia, M. (1992) HLA structure of 
the Sardinian population: a haplotype study of 551 families.  Tissue Antigens, 40 
(4),165.  
[6] Cavalli Sforza, L.L., Menozzi, P., Piazza, A. (1994) The history and geography of 
human genes. Princeton, Princeton University Press. 
[7] Crouau-Roy, B., Bouzekri, N., Carcassi, C., Clayton, J., Contu, L., Cambon-Thomsen, 
A. (1996) Strong association between microsatellites and an HLA-B, DR haplotype 
(B18-DR3): implication for microsatellite evolution. Immunogenetics, 43 (5), 255.  
[8] Piazza, A., Cappello, N., Olivetti, E., Rendine, S. (1988) A genetic history of Italy. 
Ann Hum Genet. 52, 203. 
[9] Cappello, N., Rendine, S., Griffo, R., Mameli, G.E., Succa, V., Vona, G., Piazza, A. 
(1996) Genetic analysis of Sardinia: I. data on 12 polymorphisms in 21 linguistic 
domains. Ann Hum Genet. 60(2),125. 
100 
[10] Contu, L., Carcassi, C., Orrù, S., Mulargia, M., Arras, M., Boero, R., Gessa, S., 
Loizedda, A.L., Lai, S., Floris, L. (1998) HLA-B35 frequency variations correlate 
with malaria infection in Sardinia. Tissue Antigens, 52 (5), 452.  
[11] Lampis, R., Morelli, L., Congia, M., Macis, M.D., Mulargia, A., Loddo, M., De 
Virgiliis, S., Marrosu, M.G., Todd, J.A., Cucca, F. (2000) The inter-regional 
distribution of HLA class II haplotypes indicates the suitability of the Sardinian 
population for case-control association studies in complex diseases. Hum Mol Genet., 
9 (20), 2959.  
[12] Songini, M., Casu, A. (2005) Epidemiology of childhood diabetes.  Acta Biomed.,76, 
19. 
[13] Karvonen, M., Tuomilehto, J., Libman, I., La Porte, R. (1993) A review of the recent 
epidemiological data on the worldwide incidence of type 1 (insulin-dependent) 
diabetes mellitus. Diabetologia 36, 883–892. 
[14] Pugliatti M, Rosati G, Carton H et al: The epidemiology of multiple sclerosis in 
Europe.Eur J Neurol 2006; 13: 700–722. 
[15] McCarroll, S.A., Kuruvilla, F.G., Korn, J.M., Cawley, S., Nemesh, J., Wysoker, A., 
Shapero, M.H., de Bakker, P.I., Maller, J.B., Kirby, A., et al. (2008) Integrated 
detection and population genetic analysis of SNPs and copy number variation. Nat. 
Genet., 40, 1166-1174. 
[16] Sabeti PC, Varilly P, Fry B et al: Genome-wide detection and characterization of 
positive selection in human populations. Nature 2007; 449: 913–918. 
[17] Simonson TS, Yang Y, Huff CD et al: Genetic evidence for high-altitude adaptation in 
Tibet. Science 2010; 329: 72–75. 
[18] Williamson SH, Hubisz MJ, Clark AG et al: Localizing recent adaptive evolution in 
the human genome. Plos Genet 2007; 3: e90. 
[19] Tognotti E: La Malaria in Sardegna – Per Una Storia Del Paludismo Nel Mezzogiorno 
(1880–1950), In Franco Angeli (ed). Milano, 1996.  
[20] Fermi C: Le Regioni Malariche. Decadenza e Risanamento E Spesa ‘Sardegna’,Vol I: 
Roma: Tipografia editrice di Roma S.A, 1934.  
101 
[21] Fermi C: Provincia Di Nuoro. Malaria, Danni Economici, Risanamento E Proposte Per 
Il Suo Risorgimento, Vol II:Sassari: Stamperia della libreria italiana e  straniera, 1938. 
[22] Myles S, Davison D, Barrett J et al: Worldwide population differentiation at disease-
associated SNPs. BMC Med Genomics 2008; 1: 22.
102 
 
4.2. Study No. 2, 
In collaboration with researchers from the following international institutions: 
Department of Animal and Plant Sciences, University of Sheffield, Western Bank, Sheffield, 
S10 2TN, UK - Department of Mental Health, Johns Hopkins University Bloomberg School 
of Public Health, Baltimore, Maryland 21205, USA -  Department of Pediatrics, Keck School 
of Medicine and Children’s Hospital Los Angeles, University of Southern California, Los 
Angeles, California 90027, USA - T.T. Chang Genetic Resources Center, International Rice 
Research Institute, Los Ban˜os, Laguna , Philippines. - Department of Sciences of Life and 
Environment, University of Cagliari Italy, - Department of Biology, University of Pisa, Italy, 
- Department of Science of Nature and Territory, University of Sassari, Italy, - The Wellcome 
Trust Sanger Institute, Hinxton CB10 1SA, UK, - Department of Anthropology, University of 
Pennsylvania, Philadelphia, Pennsylvania, 19104, USA, - Departamento de Toxicologı ´a, 
Cinvestav, San Pedro Zacatenco, CP 07360, Mexico. 12 Instituto de Gene´tica y Biologı ´a 
Molecular, University of San Martin de Porres, Lima, Peru, - Departamento de Biologia 
Geral, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, - Institut de Biologia 
Evolutiva (CSIC-UPF), Departament de Ciences de la Salut i de la Vida, Universitat Pompeu 
Fabra, 08003 Barcelona, Spain, - Vavilov Institute for General Genetics: Moscow, Russia, - 
Research Centre for Medical Genetics, Moscow, Russia, - The Lebanese American 
University, Chouran, Beirut, Lebanon, National Health Laboratory Service, Johannesburg, 
South Africa, - The Genographic Laboratory, School of Biological Sciences, Madurai 
Kamaraj University, Madurai, India, Department of ecology and evolutionary biology, 
University of Arizona, Tucson, Arizona 85721, USA, - Department of Anatomy, University 
of Otago, Dunedin 9054, New Zealand, - National Geographic Society,Washington, District 
of Columbia 20036, USA, that ended with the article 
http://www.ncbi.nlm.nih.gov/pubmed/24781250, Elhaik E, Tatarinova T, Chebotarev D, Piras 
IS, Maria Calò C, De Montis A, Atzori M, Marini M, Tofanelli S, Francalacci P, Pagani L, 
Tyler-Smith C, Xue Y, Cucca F, Schurr TG, Gaieski JB, Melendez C, Vilar MG, Owings AC, 
Gómez R, Fujita R, Santos FR, Comas D, Balanovsky O, Balanovska E, Zalloua P, Soodyall 
H, Pitchappan R, Ganeshprasad A, Hammer M, Matisoo-Smith L, Wells RS; Genographic 
Consortium. Geographic population structure analysis of worldwide human populations 
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The paper proposes an algorithm to identify the geographical origin of the individuals 
using their biological data, and thus trying to overcome one of the most complex issues of 
population genetics and anthropology. In fact the nature of biological diversity, makes it hard 
to tell where one stops and the other population starts watching the simple spatial distribution 
of a feature fenotipica[1-4] but at the same time important studies[5-6] have established a 
strong relationship between the genetic characteristics of different populations and 
geographical distances separating them. These observations, has stimulated the development 
of biogeographic methods. The different biogeographical applications currently in place are 
not very precise and therefore the percentage of individuals correctly assigned to their country 
of origin, is relatively low for Europeans and very low for non Europeans[7]. The work was 
then hypothesized and a new analysis model that is based on the fundamental approach of 
mixing and genetic analysis including 100,000 ancestral informative markers (AIMs), 
reported on platforms GenChip. 
 
This analysis tool identifies the smallest number of markers sufficient to adequately 
differentiate two genetically distinct populations. It was applied to the set of public and 
private data relating to the sampled populations in various parts of the world, in order to 
validate the potential application. About 600 individuals collected in Genographic Project and 
circa 1000 DNA collected at different Genomes Project in several geographical areas around 
the world, including very heterogeneous populations such as rural populations of Kuwait[8], 
Puerto Rico and Bermuda[9], as well as the community of the same country and therefore 
theoretically closer: such as Peruvians from Lima and highland indigenous Peruvians. When 
applied to 200 Sardinians[10], the GPS Placed a quarter of them in their villages and most of 
the rest within 50km of their villages. 
 
4.2.1. Conclusion 
The work for which we have made available a part of the data set of genetic data 
concerning the Ogliastra population samples analyzed by us, describes a method of 
geographical  population structure (GPS) based on mixing which aims to predict the 
biogeographical origin of individuals worldwide from local residents. The validation 
performed on our sample and those of many other international groups valid the new 
algorithm Geographic Population Structure (GPS) by placing approximately 83% of 
worldwide individuals in their country of origin. The analysis led to the formation of clusters 
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for those subjects from the same geographic area and allowed the distinction of populations 
from different geographical areas. For each individual was possible to assign with relative 
accuracy the geographical coordinates and the distance of the supposed place of origin. 
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5. General conclusions and perspectives 
The data obtained in the second phase of my research analyzing the Biobank created in  
Ogliastra have highlighted already important characteristics of this population, useful for 
anthropological studies and validation of new tools / algorithms to be applied to the study of 
population genetics. However, the goal remains,  start a genotyping population control, 
healthy, for the study of the genes responsible for many common multifactorial diseases. The 
homogeneity of the Ogliastra population, all selected subjects (healthy controls and patients) 
strictly belonging to a single population without ethnic stratification, with the absence of 
consanguinity between until 4th or 5th generation, the absence among the controls, of family 
members with common complex diseases, and the minimum risk that some subject included 
among the controls have a latent predisposition to one or more complex diseases, along with 
the number of subjects that make sampling of controls and that among some of the most 
important complex diseases, and the complete anonymity of the subjects included in the 
Biobank, suggest that this is an ideal sample for the research of genes and gene combinations 
involved in complex diseases, through case-control association studies. 
 
The dataset of DNA samples of all feature controls will be the reference for the study of 
the most common multifactorial diseases in Ogliastra and the world. In fact they are stored in 
the same way the DNA samples of patients with multifactorial diseases, which is currently in 
progress along the whole genome genotyping and analysis of related datasets. 
 
Using combinations of genotypic susceptibility and/or protection it emerged that, you 
can identify allelic combinations or haplotype high predictive values for the detection of both 
individuals at risk or protected of disease. For example it is well known that children of 
parents with diabetes have a very high risk of developing the disease during the first decades 
of life. It would be very important to recognize early in families at risk as children have 
genetic conditions of high risk T1D, and those who have a genetic conditions of non-risk or 
protection. The prospects for effective preventive interventions in individuals at risk for T1D 
become thanks to this research increasingly concrete. 
 
 
